Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Platelet Aggregation Inhibitors | 430 | 2024 | 3070 | 33.570 |
Why?
|
Myocardial Infarction | 432 | 2024 | 11708 | 20.190 |
Why?
|
Ticlopidine | 158 | 2018 | 899 | 17.110 |
Why?
|
Acute Coronary Syndrome | 168 | 2024 | 2337 | 16.580 |
Why?
|
Coronary Artery Disease | 271 | 2024 | 6485 | 15.340 |
Why?
|
Aspirin | 221 | 2024 | 3283 | 15.040 |
Why?
|
Angioplasty, Balloon, Coronary | 144 | 2020 | 1874 | 12.810 |
Why?
|
Cardiovascular Diseases | 312 | 2024 | 15142 | 12.390 |
Why?
|
Purinergic P2Y Receptor Antagonists | 86 | 2023 | 362 | 11.790 |
Why?
|
Adenosine Monophosphate | 53 | 2022 | 275 | 11.690 |
Why?
|
Drug-Eluting Stents | 73 | 2024 | 753 | 11.460 |
Why?
|
Diabetes Mellitus, Type 2 | 182 | 2024 | 11729 | 9.740 |
Why?
|
Stents | 148 | 2023 | 3280 | 8.990 |
Why?
|
Stroke | 264 | 2024 | 9975 | 8.660 |
Why?
|
Heart Failure | 187 | 2024 | 10896 | 8.430 |
Why?
|
Eicosapentaenoic Acid | 47 | 2024 | 581 | 8.340 |
Why?
|
Coronary Artery Bypass | 79 | 2024 | 2288 | 8.040 |
Why?
|
Hypertriglyceridemia | 22 | 2024 | 295 | 7.930 |
Why?
|
Thrombosis | 119 | 2023 | 2968 | 7.930 |
Why?
|
Registries | 278 | 2023 | 8090 | 7.910 |
Why?
|
Fibrinolytic Agents | 94 | 2023 | 2159 | 7.590 |
Why?
|
Hemorrhage | 192 | 2024 | 3458 | 7.540 |
Why?
|
Anticoagulants | 116 | 2024 | 4599 | 6.950 |
Why?
|
Aortic Valve Stenosis | 46 | 2024 | 1955 | 6.950 |
Why?
|
Coronary Thrombosis | 46 | 2020 | 495 | 6.860 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 93 | 2024 | 3255 | 6.710 |
Why?
|
Hypertension | 93 | 2023 | 8480 | 6.540 |
Why?
|
Atherosclerosis | 101 | 2024 | 3445 | 6.450 |
Why?
|
Atrial Fibrillation | 100 | 2023 | 5033 | 6.280 |
Why?
|
Humans | 1950 | 2024 | 743811 | 6.190 |
Why?
|
Hospital Mortality | 141 | 2023 | 5316 | 6.010 |
Why?
|
Treatment Outcome | 584 | 2024 | 63042 | 5.770 |
Why?
|
Drug Therapy, Combination | 198 | 2024 | 6487 | 5.600 |
Why?
|
Randomized Controlled Trials as Topic | 181 | 2023 | 9944 | 5.560 |
Why?
|
Peripheral Arterial Disease | 55 | 2023 | 1188 | 5.470 |
Why?
|
Brain Ischemia | 79 | 2023 | 3264 | 5.380 |
Why?
|
Renal Artery | 18 | 2022 | 399 | 5.360 |
Why?
|
Cardiology | 48 | 2024 | 1668 | 5.320 |
Why?
|
Hypoglycemic Agents | 75 | 2024 | 2877 | 5.260 |
Why?
|
Angina, Unstable | 39 | 2023 | 926 | 5.080 |
Why?
|
Risk Factors | 528 | 2024 | 72252 | 5.070 |
Why?
|
Secondary Prevention | 70 | 2024 | 1529 | 5.060 |
Why?
|
Coronary Angiography | 91 | 2023 | 4576 | 4.900 |
Why?
|
Myocardial Revascularization | 47 | 2022 | 841 | 4.830 |
Why?
|
Adamantane | 23 | 2021 | 173 | 4.710 |
Why?
|
Patient Readmission | 59 | 2023 | 3117 | 4.630 |
Why?
|
Sympathectomy | 20 | 2023 | 89 | 4.630 |
Why?
|
Aortic Valve | 38 | 2023 | 1920 | 4.580 |
Why?
|
Renal Insufficiency, Chronic | 40 | 2023 | 2200 | 4.520 |
Why?
|
Risk Assessment | 230 | 2024 | 23327 | 4.510 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 60 | 2018 | 641 | 4.480 |
Why?
|
Dipeptides | 23 | 2021 | 409 | 4.390 |
Why?
|
Myocardial Ischemia | 50 | 2024 | 2150 | 4.390 |
Why?
|
Aged | 829 | 2024 | 163178 | 4.380 |
Why?
|
Blood Pressure | 73 | 2022 | 8551 | 4.290 |
Why?
|
Antihypertensive Agents | 44 | 2023 | 2047 | 4.250 |
Why?
|
Guideline Adherence | 68 | 2021 | 2265 | 4.240 |
Why?
|
Coronary Vessels | 36 | 2023 | 3106 | 4.070 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 22 | 2021 | 293 | 4.000 |
Why?
|
Male | 1011 | 2024 | 349776 | 4.000 |
Why?
|
Proton Pump Inhibitors | 22 | 2022 | 526 | 3.990 |
Why?
|
Heart Valve Prosthesis Implantation | 31 | 2023 | 1537 | 3.960 |
Why?
|
Coronary Vessel Anomalies | 7 | 2022 | 314 | 3.900 |
Why?
|
Coronary Stenosis | 23 | 2023 | 833 | 3.840 |
Why?
|
Coronary Disease | 70 | 2021 | 6078 | 3.770 |
Why?
|
Saphenous Vein | 19 | 2022 | 532 | 3.740 |
Why?
|
Female | 987 | 2024 | 380020 | 3.660 |
Why?
|
Coronary Restenosis | 29 | 2021 | 424 | 3.640 |
Why?
|
Thrombolytic Therapy | 49 | 2024 | 2162 | 3.620 |
Why?
|
Middle Aged | 750 | 2024 | 213241 | 3.540 |
Why?
|
Hospitalization | 116 | 2023 | 10259 | 3.430 |
Why?
|
Shock, Cardiogenic | 21 | 2023 | 688 | 3.420 |
Why?
|
Time Factors | 256 | 2021 | 40038 | 3.410 |
Why?
|
Adenosine | 26 | 2023 | 825 | 3.410 |
Why?
|
United States | 342 | 2023 | 69859 | 3.340 |
Why?
|
Glucosides | 32 | 2024 | 451 | 3.340 |
Why?
|
Graft Occlusion, Vascular | 22 | 2022 | 549 | 3.260 |
Why?
|
Warfarin | 36 | 2021 | 1497 | 3.240 |
Why?
|
Double-Blind Method | 148 | 2024 | 12020 | 3.210 |
Why?
|
Blood Platelets | 42 | 2023 | 2509 | 3.200 |
Why?
|
Clinical Trials as Topic | 60 | 2023 | 7908 | 3.170 |
Why?
|
Platelet Aggregation | 26 | 2023 | 798 | 3.140 |
Why?
|
Cholesterol, LDL | 38 | 2023 | 2354 | 3.120 |
Why?
|
Cardiovascular Agents | 26 | 2022 | 850 | 3.120 |
Why?
|
American Heart Association | 42 | 2022 | 1057 | 3.070 |
Why?
|
Practice Guidelines as Topic | 94 | 2021 | 7270 | 3.010 |
Why?
|
Peripheral Vascular Diseases | 27 | 2018 | 549 | 2.990 |
Why?
|
Tissue Plasminogen Activator | 35 | 2022 | 1263 | 2.990 |
Why?
|
Thrombectomy | 18 | 2023 | 680 | 2.980 |
Why?
|
Vascular Diseases | 21 | 2023 | 1161 | 2.960 |
Why?
|
Diabetes Mellitus | 58 | 2023 | 5752 | 2.950 |
Why?
|
Denervation | 12 | 2022 | 278 | 2.940 |
Why?
|
Benzhydryl Compounds | 37 | 2024 | 844 | 2.900 |
Why?
|
Heart Valve Prosthesis | 27 | 2023 | 1489 | 2.870 |
Why?
|
Heart Diseases | 20 | 2023 | 2789 | 2.810 |
Why?
|
Kidney | 43 | 2023 | 7185 | 2.790 |
Why?
|
Ischemic Attack, Transient | 24 | 2023 | 934 | 2.780 |
Why?
|
Antithrombins | 17 | 2020 | 304 | 2.690 |
Why?
|
Glycosides | 6 | 2023 | 107 | 2.650 |
Why?
|
Ischemia | 27 | 2022 | 1907 | 2.610 |
Why?
|
Aged, 80 and over | 294 | 2024 | 57744 | 2.590 |
Why?
|
Quality Indicators, Health Care | 25 | 2020 | 1831 | 2.530 |
Why?
|
Dyslipidemias | 19 | 2021 | 851 | 2.510 |
Why?
|
Fatty Acids, Omega-3 | 12 | 2024 | 1344 | 2.440 |
Why?
|
Gastrointestinal Hemorrhage | 19 | 2021 | 1131 | 2.440 |
Why?
|
Fractional Flow Reserve, Myocardial | 9 | 2023 | 289 | 2.430 |
Why?
|
Thromboembolism | 20 | 2023 | 987 | 2.370 |
Why?
|
Diabetes Complications | 23 | 2022 | 1360 | 2.370 |
Why?
|
Chest Pain | 16 | 2022 | 1114 | 2.360 |
Why?
|
Troponin | 15 | 2023 | 524 | 2.340 |
Why?
|
Endovascular Procedures | 26 | 2023 | 1980 | 2.320 |
Why?
|
Hypertension, Renal | 6 | 2023 | 177 | 2.310 |
Why?
|
Foramen Ovale, Patent | 6 | 2019 | 223 | 2.300 |
Why?
|
Mitral Valve Insufficiency | 13 | 2023 | 1421 | 2.290 |
Why?
|
Cardiovascular System | 14 | 2024 | 828 | 2.280 |
Why?
|
Quality of Health Care | 42 | 2020 | 4370 | 2.280 |
Why?
|
Anticholesteremic Agents | 20 | 2023 | 979 | 2.230 |
Why?
|
Catheter Ablation | 17 | 2023 | 2758 | 2.200 |
Why?
|
Follow-Up Studies | 195 | 2023 | 39001 | 2.180 |
Why?
|
Cerebrovascular Disorders | 25 | 2023 | 1504 | 2.150 |
Why?
|
Bariatric Surgery | 19 | 2022 | 952 | 2.140 |
Why?
|
Carotid Stenosis | 24 | 2021 | 854 | 2.080 |
Why?
|
Postoperative Complications | 59 | 2021 | 15281 | 2.070 |
Why?
|
Primary Prevention | 22 | 2023 | 1167 | 2.070 |
Why?
|
Cholesterol | 20 | 2024 | 2922 | 2.060 |
Why?
|
Platelet Function Tests | 26 | 2019 | 270 | 2.050 |
Why?
|
Lipid Regulating Agents | 6 | 2022 | 24 | 2.020 |
Why?
|
Inpatients | 25 | 2022 | 2515 | 2.000 |
Why?
|
Radial Artery | 11 | 2022 | 193 | 1.950 |
Why?
|
Healthcare Disparities | 25 | 2022 | 3155 | 1.950 |
Why?
|
Patient Discharge | 41 | 2023 | 3317 | 1.930 |
Why?
|
Angina Pectoris, Variant | 3 | 2020 | 55 | 1.910 |
Why?
|
Hospital Costs | 16 | 2021 | 985 | 1.890 |
Why?
|
United States Food and Drug Administration | 12 | 2022 | 1582 | 1.880 |
Why?
|
Incidence | 115 | 2023 | 20948 | 1.870 |
Why?
|
Stroke Volume | 47 | 2023 | 5002 | 1.850 |
Why?
|
Diabetic Nephropathies | 14 | 2022 | 984 | 1.810 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 11 | 2021 | 236 | 1.800 |
Why?
|
Heart Valve Diseases | 12 | 2023 | 1073 | 1.780 |
Why?
|
Coronary Occlusion | 6 | 2021 | 304 | 1.770 |
Why?
|
Hypercholesterolemia | 17 | 2020 | 1151 | 1.750 |
Why?
|
Risk Reduction Behavior | 16 | 2020 | 1125 | 1.750 |
Why?
|
Electrocardiography | 40 | 2021 | 6441 | 1.750 |
Why?
|
Databases, Factual | 48 | 2021 | 7729 | 1.700 |
Why?
|
Hospitals | 36 | 2022 | 3953 | 1.690 |
Why?
|
Drug Resistance | 21 | 2018 | 1606 | 1.680 |
Why?
|
Diabetic Angiopathies | 17 | 2019 | 819 | 1.670 |
Why?
|
Sirolimus | 13 | 2018 | 1565 | 1.670 |
Why?
|
Survival Rate | 81 | 2021 | 12786 | 1.660 |
Why?
|
Thiophenes | 14 | 2015 | 589 | 1.660 |
Why?
|
Triglycerides | 20 | 2024 | 2453 | 1.640 |
Why?
|
Omeprazole | 7 | 2016 | 112 | 1.630 |
Why?
|
Obesity | 43 | 2024 | 12744 | 1.620 |
Why?
|
Mitral Valve | 13 | 2023 | 1491 | 1.610 |
Why?
|
Drug Administration Schedule | 53 | 2021 | 4931 | 1.600 |
Why?
|
Immunoglobulin Fab Fragments | 21 | 2017 | 482 | 1.600 |
Why?
|
Blood Vessel Prosthesis Implantation | 20 | 2023 | 1391 | 1.600 |
Why?
|
Angina Pectoris | 11 | 2022 | 977 | 1.590 |
Why?
|
Out-of-Hospital Cardiac Arrest | 8 | 2023 | 339 | 1.560 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 18 | 2023 | 1516 | 1.550 |
Why?
|
Diastole | 7 | 2020 | 791 | 1.530 |
Why?
|
Retrospective Studies | 197 | 2024 | 77410 | 1.530 |
Why?
|
Sodium-Glucose Transporter 2 | 9 | 2023 | 85 | 1.500 |
Why?
|
Atrial Appendage | 7 | 2023 | 282 | 1.500 |
Why?
|
Health Behavior | 12 | 2016 | 2634 | 1.440 |
Why?
|
Medication Adherence | 15 | 2023 | 2063 | 1.440 |
Why?
|
Platelet Activation | 13 | 2017 | 674 | 1.430 |
Why?
|
Plaque, Atherosclerotic | 10 | 2022 | 1518 | 1.420 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 9 | 2013 | 257 | 1.420 |
Why?
|
Metals | 10 | 2019 | 719 | 1.410 |
Why?
|
Hypolipidemic Agents | 14 | 2021 | 606 | 1.410 |
Why?
|
Research Design | 29 | 2022 | 5983 | 1.410 |
Why?
|
Recurrence | 55 | 2023 | 8337 | 1.400 |
Why?
|
Quality Improvement | 29 | 2022 | 3750 | 1.390 |
Why?
|
Influenza, Human | 10 | 2023 | 1480 | 1.390 |
Why?
|
Myocardial Reperfusion | 10 | 2017 | 351 | 1.390 |
Why?
|
Intracranial Hemorrhages | 24 | 2023 | 855 | 1.380 |
Why?
|
Dose-Response Relationship, Drug | 65 | 2021 | 10940 | 1.370 |
Why?
|
Anti-Arrhythmia Agents | 8 | 2023 | 788 | 1.360 |
Why?
|
Incretins | 5 | 2021 | 88 | 1.360 |
Why?
|
Odds Ratio | 72 | 2022 | 9848 | 1.350 |
Why?
|
Renal Dialysis | 15 | 2024 | 1783 | 1.340 |
Why?
|
Sodium-Glucose Transporter 1 | 4 | 2021 | 112 | 1.340 |
Why?
|
Adrenergic beta-Antagonists | 18 | 2022 | 1240 | 1.330 |
Why?
|
Fibromuscular Dysplasia | 2 | 2019 | 58 | 1.310 |
Why?
|
Exercise Test | 10 | 2020 | 2074 | 1.310 |
Why?
|
Systole | 10 | 2020 | 958 | 1.300 |
Why?
|
Aortic Aneurysm, Abdominal | 9 | 2020 | 1187 | 1.300 |
Why?
|
Masks | 2 | 2021 | 197 | 1.290 |
Why?
|
Administration, Oral | 43 | 2023 | 3912 | 1.280 |
Why?
|
Prosthesis Design | 29 | 2023 | 2103 | 1.270 |
Why?
|
Health Status | 15 | 2023 | 4031 | 1.250 |
Why?
|
Bioprosthesis | 9 | 2020 | 597 | 1.250 |
Why?
|
Patient Selection | 33 | 2020 | 4210 | 1.240 |
Why?
|
Placebos | 7 | 2020 | 1674 | 1.230 |
Why?
|
Carotid Arteries | 11 | 2021 | 949 | 1.230 |
Why?
|
Femoral Artery | 11 | 2021 | 845 | 1.220 |
Why?
|
Proportional Hazards Models | 86 | 2022 | 12354 | 1.220 |
Why?
|
Cause of Death | 41 | 2021 | 3580 | 1.200 |
Why?
|
Prevalence | 63 | 2022 | 15211 | 1.200 |
Why?
|
Palliative Care | 5 | 2022 | 3490 | 1.190 |
Why?
|
Angiotensin Receptor Antagonists | 12 | 2023 | 923 | 1.190 |
Why?
|
Coronary Circulation | 13 | 2023 | 1572 | 1.190 |
Why?
|
Cardiac Surgical Procedures | 14 | 2024 | 3537 | 1.190 |
Why?
|
Chi-Square Distribution | 39 | 2018 | 3503 | 1.170 |
Why?
|
Survival Analysis | 64 | 2021 | 10251 | 1.170 |
Why?
|
Troponin T | 13 | 2023 | 754 | 1.160 |
Why?
|
Pacemaker, Artificial | 7 | 2023 | 815 | 1.160 |
Why?
|
Albuminuria | 7 | 2023 | 681 | 1.160 |
Why?
|
Glucagon-Like Peptides | 6 | 2024 | 127 | 1.160 |
Why?
|
Pandemics | 15 | 2022 | 8385 | 1.160 |
Why?
|
Heparin | 18 | 2020 | 1637 | 1.140 |
Why?
|
Multivariate Analysis | 72 | 2020 | 12243 | 1.140 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 13 | 2019 | 2281 | 1.140 |
Why?
|
Disease Management | 15 | 2021 | 2459 | 1.140 |
Why?
|
Endarterectomy, Carotid | 14 | 2018 | 546 | 1.130 |
Why?
|
Sex Factors | 41 | 2021 | 10394 | 1.110 |
Why?
|
Defibrillators, Implantable | 12 | 2019 | 1439 | 1.110 |
Why?
|
Comorbidity | 54 | 2023 | 10380 | 1.100 |
Why?
|
Prognosis | 88 | 2024 | 29052 | 1.100 |
Why?
|
Cardiopulmonary Resuscitation | 8 | 2023 | 980 | 1.090 |
Why?
|
Coronavirus Infections | 9 | 2020 | 3134 | 1.090 |
Why?
|
Pneumonia, Viral | 9 | 2020 | 3241 | 1.080 |
Why?
|
Logistic Models | 59 | 2023 | 13404 | 1.080 |
Why?
|
Age Factors | 60 | 2021 | 18355 | 1.070 |
Why?
|
Incidental Findings | 2 | 2021 | 689 | 1.060 |
Why?
|
Kidney Failure, Chronic | 13 | 2022 | 2534 | 1.060 |
Why?
|
Patient Admission | 12 | 2019 | 1380 | 1.050 |
Why?
|
Kaplan-Meier Estimate | 48 | 2020 | 6539 | 1.050 |
Why?
|
Atrial Flutter | 6 | 2023 | 263 | 1.050 |
Why?
|
Absorbable Implants | 7 | 2019 | 336 | 1.050 |
Why?
|
Paclitaxel | 8 | 2012 | 1705 | 1.050 |
Why?
|
Arteritis | 3 | 2019 | 159 | 1.040 |
Why?
|
Diabetic Cardiomyopathies | 7 | 2019 | 95 | 1.030 |
Why?
|
Receptors, Purinergic P2Y12 | 9 | 2019 | 132 | 1.030 |
Why?
|
Blood Glucose | 24 | 2022 | 6259 | 1.020 |
Why?
|
Prospective Studies | 149 | 2024 | 53250 | 1.020 |
Why?
|
Blood Loss, Surgical | 3 | 2019 | 660 | 1.010 |
Why?
|
Mineral Oil | 3 | 2023 | 25 | 1.010 |
Why?
|
Thrombophilia | 2 | 2019 | 305 | 1.010 |
Why?
|
Heart | 8 | 2024 | 4460 | 1.010 |
Why?
|
Predictive Value of Tests | 57 | 2023 | 15067 | 0.990 |
Why?
|
Adult | 174 | 2023 | 213889 | 0.980 |
Why?
|
Coronary Vasospasm | 2 | 2016 | 88 | 0.980 |
Why?
|
Ventricular Function, Left | 17 | 2023 | 3660 | 0.970 |
Why?
|
Pulmonary Valve | 2 | 2018 | 437 | 0.970 |
Why?
|
Lipoprotein(a) | 11 | 2024 | 435 | 0.970 |
Why?
|
Perioperative Care | 8 | 2021 | 1002 | 0.970 |
Why?
|
Medicare | 41 | 2023 | 6565 | 0.960 |
Why?
|
Diabetic Ketoacidosis | 4 | 2022 | 247 | 0.960 |
Why?
|
Hirudins | 14 | 2020 | 183 | 0.960 |
Why?
|
Propensity Score | 23 | 2021 | 1781 | 0.950 |
Why?
|
Research Report | 3 | 2021 | 355 | 0.950 |
Why?
|
Renal Insufficiency | 9 | 2024 | 805 | 0.950 |
Why?
|
Echocardiography, Transesophageal | 7 | 2020 | 1133 | 0.950 |
Why?
|
Piperazines | 11 | 2015 | 2487 | 0.950 |
Why?
|
Length of Stay | 35 | 2021 | 6311 | 0.940 |
Why?
|
Drug Substitution | 8 | 2021 | 281 | 0.940 |
Why?
|
Infusions, Intravenous | 20 | 2023 | 2274 | 0.940 |
Why?
|
Hyperlipidemias | 9 | 2024 | 789 | 0.920 |
Why?
|
C-Reactive Protein | 25 | 2024 | 3778 | 0.920 |
Why?
|
Nephritis | 2 | 2023 | 159 | 0.920 |
Why?
|
Evidence-Based Medicine | 25 | 2020 | 3608 | 0.910 |
Why?
|
Angioplasty, Balloon | 9 | 2020 | 653 | 0.910 |
Why?
|
Cohort Studies | 92 | 2024 | 40545 | 0.910 |
Why?
|
Drug Approval | 4 | 2021 | 742 | 0.910 |
Why?
|
Embolic Protection Devices | 3 | 2021 | 42 | 0.900 |
Why?
|
Aortic Valve Insufficiency | 4 | 2023 | 579 | 0.900 |
Why?
|
Tachycardia, Ventricular | 5 | 2023 | 1272 | 0.900 |
Why?
|
Postoperative Care | 7 | 2020 | 1485 | 0.890 |
Why?
|
Prosthesis Failure | 8 | 2022 | 1203 | 0.890 |
Why?
|
Nutrition Surveys | 9 | 2022 | 1660 | 0.880 |
Why?
|
Anemia | 7 | 2021 | 1502 | 0.880 |
Why?
|
Arteriosclerosis | 9 | 2013 | 1092 | 0.870 |
Why?
|
Leg | 3 | 2016 | 1116 | 0.870 |
Why?
|
Antibodies, Monoclonal | 26 | 2023 | 9272 | 0.870 |
Why?
|
Severity of Illness Index | 50 | 2023 | 15526 | 0.870 |
Why?
|
Gastrectomy | 9 | 2022 | 663 | 0.870 |
Why?
|
Phospholipids | 4 | 2022 | 784 | 0.860 |
Why?
|
Imines | 6 | 2012 | 33 | 0.860 |
Why?
|
Rheumatic Heart Disease | 2 | 2023 | 177 | 0.860 |
Why?
|
Peptide Fragments | 22 | 2024 | 5096 | 0.850 |
Why?
|
Carotid Artery Diseases | 10 | 2018 | 875 | 0.850 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2022 | 59 | 0.850 |
Why?
|
Tissue and Organ Harvesting | 5 | 2022 | 369 | 0.840 |
Why?
|
Glomerular Filtration Rate | 21 | 2023 | 2167 | 0.840 |
Why?
|
Postoperative Hemorrhage | 9 | 2020 | 409 | 0.840 |
Why?
|
Ventricular Outflow Obstruction | 3 | 2021 | 272 | 0.840 |
Why?
|
Clinical Trials, Phase III as Topic | 10 | 2022 | 841 | 0.830 |
Why?
|
Cardiology Service, Hospital | 3 | 2019 | 246 | 0.830 |
Why?
|
Tobacco Use Disorder | 2 | 2021 | 688 | 0.830 |
Why?
|
Risk | 30 | 2019 | 9677 | 0.810 |
Why?
|
Gastric Bypass | 11 | 2021 | 812 | 0.810 |
Why?
|
Cardiac Imaging Techniques | 2 | 2022 | 269 | 0.810 |
Why?
|
Ventricular Dysfunction, Left | 8 | 2022 | 2074 | 0.800 |
Why?
|
Artificial Intelligence | 6 | 2023 | 2210 | 0.800 |
Why?
|
Acute Disease | 41 | 2022 | 7150 | 0.800 |
Why?
|
Erythrocyte Transfusion | 3 | 2019 | 565 | 0.790 |
Why?
|
Pyridones | 8 | 2018 | 711 | 0.770 |
Why?
|
Eligibility Determination | 3 | 2021 | 404 | 0.760 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2020 | 858 | 0.750 |
Why?
|
Acute Kidney Injury | 14 | 2022 | 1968 | 0.750 |
Why?
|
Poverty | 5 | 2022 | 2660 | 0.740 |
Why?
|
Mitral Valve Annuloplasty | 2 | 2019 | 143 | 0.740 |
Why?
|
Body Mass Index | 34 | 2024 | 12718 | 0.730 |
Why?
|
Cost-Benefit Analysis | 20 | 2023 | 5388 | 0.730 |
Why?
|
Vitamin E | 2 | 2015 | 868 | 0.720 |
Why?
|
Weight Loss | 14 | 2022 | 2625 | 0.720 |
Why?
|
Attitude to Health | 3 | 2021 | 2052 | 0.720 |
Why?
|
Periodontitis | 2 | 2022 | 552 | 0.720 |
Why?
|
Electric Countershock | 3 | 2018 | 534 | 0.710 |
Why?
|
Congresses as Topic | 5 | 2018 | 763 | 0.710 |
Why?
|
Creatine Kinase, MB Form | 9 | 2013 | 214 | 0.710 |
Why?
|
Recovery of Function | 14 | 2021 | 2922 | 0.710 |
Why?
|
Hospitals, Teaching | 7 | 2018 | 1180 | 0.710 |
Why?
|
Cardiotoxins | 1 | 2019 | 41 | 0.700 |
Why?
|
Translating | 1 | 2020 | 144 | 0.700 |
Why?
|
Health Resources | 4 | 2020 | 912 | 0.700 |
Why?
|
Aortic Aneurysm, Thoracic | 2 | 2017 | 691 | 0.700 |
Why?
|
2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2014 | 35 | 0.690 |
Why?
|
Embolism | 7 | 2020 | 407 | 0.690 |
Why?
|
Angioplasty | 6 | 2020 | 364 | 0.680 |
Why?
|
Pyridines | 15 | 2018 | 2827 | 0.680 |
Why?
|
Multicenter Studies as Topic | 15 | 2022 | 1676 | 0.680 |
Why?
|
Heart Rate | 12 | 2023 | 4091 | 0.680 |
Why?
|
Intracranial Thrombosis | 1 | 2020 | 113 | 0.670 |
Why?
|
Coagulants | 1 | 2019 | 49 | 0.670 |
Why?
|
Diffusion of Innovation | 2 | 2021 | 725 | 0.670 |
Why?
|
Career Choice | 2 | 2015 | 743 | 0.670 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 552 | 0.670 |
Why?
|
Social Class | 6 | 2020 | 1997 | 0.660 |
Why?
|
Influenza Vaccines | 6 | 2023 | 738 | 0.660 |
Why?
|
Smoking | 24 | 2024 | 8984 | 0.660 |
Why?
|
Receptors, Purinergic P2Y1 | 2 | 2016 | 40 | 0.660 |
Why?
|
Anti-Inflammatory Agents | 4 | 2021 | 1789 | 0.650 |
Why?
|
Anti-Obesity Agents | 2 | 2021 | 217 | 0.650 |
Why?
|
Periodontal Diseases | 1 | 2022 | 447 | 0.650 |
Why?
|
Sleep | 7 | 2021 | 4619 | 0.650 |
Why?
|
Cholesterol, HDL | 6 | 2023 | 1813 | 0.650 |
Why?
|
Catheterization, Peripheral | 5 | 2021 | 345 | 0.650 |
Why?
|
Venous Thromboembolism | 8 | 2024 | 1670 | 0.640 |
Why?
|
Heart Transplantation | 4 | 2023 | 3113 | 0.640 |
Why?
|
Awareness | 2 | 2020 | 639 | 0.640 |
Why?
|
Athletes | 2 | 2016 | 1093 | 0.640 |
Why?
|
Breast Implants | 1 | 2022 | 387 | 0.640 |
Why?
|
Pyrazoles | 11 | 2018 | 1970 | 0.640 |
Why?
|
Inflammation | 23 | 2024 | 10629 | 0.620 |
Why?
|
Hemodynamics | 11 | 2020 | 4197 | 0.620 |
Why?
|
Myocardium | 6 | 2020 | 4775 | 0.620 |
Why?
|
Diagnostic Imaging | 3 | 2021 | 3503 | 0.620 |
Why?
|
Autonomic Denervation | 2 | 2016 | 6 | 0.610 |
Why?
|
Mortality | 24 | 2023 | 2862 | 0.610 |
Why?
|
Education, Medical, Continuing | 2 | 2020 | 840 | 0.610 |
Why?
|
Receptor, PAR-1 | 5 | 2012 | 113 | 0.610 |
Why?
|
Smoking Cessation | 9 | 2020 | 2071 | 0.610 |
Why?
|
Calculi | 1 | 2017 | 46 | 0.610 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 2022 | 277 | 0.600 |
Why?
|
Drug Labeling | 2 | 2019 | 233 | 0.600 |
Why?
|
Coronary Aneurysm | 2 | 2018 | 237 | 0.600 |
Why?
|
Renin-Angiotensin System | 5 | 2023 | 758 | 0.600 |
Why?
|
Viremia | 1 | 2020 | 736 | 0.600 |
Why?
|
Coated Materials, Biocompatible | 5 | 2020 | 318 | 0.600 |
Why?
|
Drug Interactions | 13 | 2017 | 1460 | 0.600 |
Why?
|
Diuretics | 3 | 2022 | 591 | 0.590 |
Why?
|
Potassium | 1 | 2021 | 1336 | 0.590 |
Why?
|
Mandatory Reporting | 1 | 2018 | 122 | 0.590 |
Why?
|
Cerebral Hemorrhage | 13 | 2023 | 2647 | 0.590 |
Why?
|
Metoprolol | 2 | 2015 | 93 | 0.580 |
Why?
|
Uvula | 1 | 2016 | 16 | 0.580 |
Why?
|
Toothpastes | 1 | 2016 | 12 | 0.580 |
Why?
|
Diagnostic Errors | 2 | 2022 | 1256 | 0.580 |
Why?
|
Cardiotonic Agents | 6 | 2019 | 535 | 0.570 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 2018 | 151 | 0.570 |
Why?
|
Societies, Medical | 14 | 2021 | 3740 | 0.570 |
Why?
|
Reimbursement, Incentive | 2 | 2019 | 540 | 0.570 |
Why?
|
Kidney Diseases | 10 | 2023 | 2146 | 0.570 |
Why?
|
Embolization, Therapeutic | 5 | 2014 | 1392 | 0.560 |
Why?
|
Sodium Dodecyl Sulfate | 1 | 2016 | 131 | 0.560 |
Why?
|
Defibrillators | 1 | 2016 | 37 | 0.560 |
Why?
|
Anthracyclines | 1 | 2018 | 288 | 0.560 |
Why?
|
Consensus | 12 | 2020 | 2954 | 0.560 |
Why?
|
Gastrointestinal Diseases | 4 | 2016 | 1171 | 0.550 |
Why?
|
Ventricular Remodeling | 3 | 2019 | 1225 | 0.550 |
Why?
|
Stomatitis, Aphthous | 1 | 2016 | 53 | 0.550 |
Why?
|
Seasons | 3 | 2022 | 1493 | 0.550 |
Why?
|
Death, Sudden, Cardiac | 12 | 2021 | 1542 | 0.540 |
Why?
|
Dinucleoside Phosphates | 1 | 2016 | 74 | 0.540 |
Why?
|
Immunosuppressive Agents | 6 | 2020 | 4152 | 0.540 |
Why?
|
Drug Tolerance | 2 | 2017 | 376 | 0.540 |
Why?
|
Antirheumatic Agents | 5 | 2023 | 1338 | 0.540 |
Why?
|
Decision Making | 6 | 2022 | 3887 | 0.540 |
Why?
|
Antioxidants | 3 | 2018 | 1658 | 0.540 |
Why?
|
Blood Coagulation | 8 | 2024 | 1127 | 0.530 |
Why?
|
Obesity, Morbid | 10 | 2021 | 1213 | 0.530 |
Why?
|
Docosahexaenoic Acids | 7 | 2024 | 877 | 0.530 |
Why?
|
Patient Care Team | 6 | 2022 | 2528 | 0.530 |
Why?
|
Forecasting | 10 | 2022 | 2950 | 0.530 |
Why?
|
Quality Assurance, Health Care | 9 | 2017 | 2211 | 0.530 |
Why?
|
Vascular Surgical Procedures | 4 | 2020 | 1476 | 0.530 |
Why?
|
Outpatients | 15 | 2018 | 1488 | 0.530 |
Why?
|
Electronic Health Records | 13 | 2021 | 4467 | 0.530 |
Why?
|
Blood Pressure Determination | 6 | 2020 | 633 | 0.530 |
Why?
|
Mitral Valve Stenosis | 3 | 2023 | 376 | 0.530 |
Why?
|
Myocardial Bridging | 1 | 2015 | 11 | 0.520 |
Why?
|
Information Dissemination | 3 | 2018 | 1099 | 0.520 |
Why?
|
Intention to Treat Analysis | 8 | 2021 | 426 | 0.520 |
Why?
|
Rural Population | 4 | 2020 | 2207 | 0.520 |
Why?
|
Gastroparesis | 1 | 2017 | 131 | 0.510 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2020 | 717 | 0.510 |
Why?
|
School Health Services | 2 | 2016 | 375 | 0.510 |
Why?
|
Peptides | 9 | 2016 | 4406 | 0.510 |
Why?
|
Blood Flow Velocity | 4 | 2018 | 1423 | 0.510 |
Why?
|
Dyspepsia | 2 | 2016 | 115 | 0.510 |
Why?
|
Arthritis, Rheumatoid | 7 | 2024 | 3712 | 0.510 |
Why?
|
Gagging | 1 | 2014 | 4 | 0.510 |
Why?
|
Patient Acceptance of Health Care | 5 | 2022 | 3020 | 0.510 |
Why?
|
Natriuretic Peptide, Brain | 12 | 2024 | 1572 | 0.510 |
Why?
|
Assisted Circulation | 1 | 2015 | 103 | 0.510 |
Why?
|
Ultrasonography, Interventional | 12 | 2023 | 1486 | 0.510 |
Why?
|
Age Distribution | 9 | 2019 | 2899 | 0.500 |
Why?
|
Forearm | 2 | 2016 | 409 | 0.500 |
Why?
|
Europe | 19 | 2021 | 3336 | 0.500 |
Why?
|
Leukocyte Count | 7 | 2006 | 1588 | 0.500 |
Why?
|
Referral and Consultation | 6 | 2018 | 3530 | 0.500 |
Why?
|
Stockings, Compression | 1 | 2014 | 37 | 0.500 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 546 | 0.500 |
Why?
|
Tablets, Enteric-Coated | 2 | 2022 | 23 | 0.500 |
Why?
|
Heart Injuries | 3 | 2021 | 210 | 0.500 |
Why?
|
Periodicals as Topic | 6 | 2021 | 1429 | 0.490 |
Why?
|
United States Department of Veterans Affairs | 9 | 2020 | 875 | 0.490 |
Why?
|
Calcium Channel Agonists | 1 | 2014 | 29 | 0.490 |
Why?
|
Venous Thrombosis | 6 | 2020 | 1240 | 0.490 |
Why?
|
Neoplasms | 17 | 2024 | 21675 | 0.490 |
Why?
|
Potassium Deficiency | 1 | 2014 | 10 | 0.490 |
Why?
|
Health Knowledge, Attitudes, Practice | 9 | 2021 | 3921 | 0.490 |
Why?
|
Pericarditis | 2 | 2022 | 128 | 0.490 |
Why?
|
Patient Education as Topic | 7 | 2021 | 2278 | 0.490 |
Why?
|
Counterpulsation | 2 | 2015 | 19 | 0.490 |
Why?
|
Heart Murmurs | 1 | 2014 | 94 | 0.490 |
Why?
|
Communicable Disease Control | 1 | 2021 | 856 | 0.480 |
Why?
|
Lipoproteins | 1 | 2019 | 881 | 0.480 |
Why?
|
Renal Artery Obstruction | 5 | 2014 | 248 | 0.480 |
Why?
|
Internal Mammary-Coronary Artery Anastomosis | 1 | 2014 | 33 | 0.480 |
Why?
|
Drug Utilization | 6 | 2019 | 1183 | 0.480 |
Why?
|
Heart Conduction System | 4 | 2016 | 1047 | 0.480 |
Why?
|
Health Status Disparities | 5 | 2021 | 1796 | 0.480 |
Why?
|
Drug Prescriptions | 4 | 2018 | 1636 | 0.470 |
Why?
|
Combined Modality Therapy | 22 | 2020 | 8637 | 0.470 |
Why?
|
Autonomic Nerve Block | 1 | 2014 | 72 | 0.470 |
Why?
|
Therapies, Investigational | 1 | 2015 | 112 | 0.470 |
Why?
|
Potassium, Dietary | 1 | 2014 | 96 | 0.470 |
Why?
|
Intra-Aortic Balloon Pumping | 4 | 2018 | 219 | 0.470 |
Why?
|
Sex Distribution | 10 | 2019 | 2298 | 0.470 |
Why?
|
Canada | 16 | 2024 | 2064 | 0.460 |
Why?
|
Ventricular Premature Complexes | 1 | 2014 | 111 | 0.460 |
Why?
|
Drug Delivery Systems | 6 | 2007 | 2217 | 0.460 |
Why?
|
Schools, Medical | 1 | 2020 | 879 | 0.460 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2015 | 648 | 0.460 |
Why?
|
Drug Monitoring | 4 | 2021 | 953 | 0.460 |
Why?
|
Diabetic Neuropathies | 1 | 2017 | 400 | 0.460 |
Why?
|
Medical Records | 2 | 2018 | 1412 | 0.450 |
Why?
|
Medicaid | 8 | 2021 | 2736 | 0.450 |
Why?
|
Veterans | 5 | 2023 | 2519 | 0.450 |
Why?
|
Fasting | 5 | 2020 | 1590 | 0.450 |
Why?
|
Vitamin K | 3 | 2023 | 295 | 0.450 |
Why?
|
Diagnostic Techniques, Cardiovascular | 4 | 2017 | 153 | 0.450 |
Why?
|
Ambulatory Care | 10 | 2020 | 2707 | 0.450 |
Why?
|
Recombinant Proteins | 16 | 2020 | 6620 | 0.450 |
Why?
|
Accreditation | 4 | 2021 | 452 | 0.450 |
Why?
|
Thrombocytopenia | 3 | 2018 | 1178 | 0.450 |
Why?
|
Injections, Intravenous | 7 | 2017 | 1422 | 0.450 |
Why?
|
Biomedical Technology | 1 | 2015 | 220 | 0.440 |
Why?
|
Lipids | 7 | 2023 | 3307 | 0.440 |
Why?
|
Thiazolidinediones | 4 | 2015 | 475 | 0.440 |
Why?
|
Infection Control | 1 | 2020 | 964 | 0.440 |
Why?
|
Echocardiography | 14 | 2022 | 5096 | 0.440 |
Why?
|
Students | 2 | 2020 | 1647 | 0.440 |
Why?
|
Device Removal | 2 | 2017 | 655 | 0.430 |
Why?
|
Life Style | 7 | 2017 | 3833 | 0.430 |
Why?
|
Chromium Alloys | 1 | 2012 | 77 | 0.430 |
Why?
|
Endothelium, Vascular | 5 | 2017 | 4459 | 0.430 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2021 | 1209 | 0.430 |
Why?
|
Single-Blind Method | 7 | 2022 | 1586 | 0.430 |
Why?
|
Enalapril | 2 | 2017 | 327 | 0.430 |
Why?
|
Tropanes | 3 | 2021 | 51 | 0.430 |
Why?
|
Vulnerable Populations | 1 | 2018 | 685 | 0.430 |
Why?
|
HIV | 1 | 2020 | 1604 | 0.430 |
Why?
|
Popliteal Artery | 3 | 2018 | 317 | 0.430 |
Why?
|
Endpoint Determination | 6 | 2021 | 601 | 0.430 |
Why?
|
Drugs, Investigational | 2 | 2016 | 214 | 0.420 |
Why?
|
Health Policy | 4 | 2021 | 2662 | 0.420 |
Why?
|
Heart-Assist Devices | 6 | 2021 | 1195 | 0.420 |
Why?
|
Piperidines | 10 | 2024 | 1601 | 0.420 |
Why?
|
Models, Cardiovascular | 6 | 2015 | 996 | 0.420 |
Why?
|
Adenosine Diphosphate | 6 | 2013 | 425 | 0.420 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 4 | 2015 | 452 | 0.420 |
Why?
|
Sex Characteristics | 7 | 2017 | 2583 | 0.410 |
Why?
|
Abdominal Fat | 1 | 2014 | 223 | 0.410 |
Why?
|
Hypoglycemia | 7 | 2019 | 861 | 0.410 |
Why?
|
Delivery of Health Care | 6 | 2020 | 5319 | 0.410 |
Why?
|
Tachycardia, Supraventricular | 1 | 2014 | 263 | 0.410 |
Why?
|
Cross-Sectional Studies | 25 | 2023 | 25032 | 0.410 |
Why?
|
Vaccination | 5 | 2022 | 3275 | 0.410 |
Why?
|
Enoxaparin | 5 | 2023 | 377 | 0.410 |
Why?
|
Residence Characteristics | 5 | 2018 | 2050 | 0.410 |
Why?
|
Algorithms | 15 | 2022 | 13869 | 0.410 |
Why?
|
Drug Design | 2 | 2015 | 1075 | 0.410 |
Why?
|
Critical Care | 5 | 2020 | 2647 | 0.410 |
Why?
|
Health Services Accessibility | 9 | 2022 | 5136 | 0.410 |
Why?
|
Cyclooxygenase Inhibitors | 3 | 2019 | 371 | 0.410 |
Why?
|
Schools | 1 | 2020 | 1432 | 0.400 |
Why?
|
Biomedical Research | 6 | 2020 | 3308 | 0.400 |
Why?
|
Mammaplasty | 1 | 2022 | 1204 | 0.400 |
Why?
|
Independent Living | 2 | 2013 | 569 | 0.400 |
Why?
|
Muscarinic Antagonists | 3 | 2021 | 137 | 0.400 |
Why?
|
Syncope | 1 | 2014 | 429 | 0.400 |
Why?
|
Psoriasis | 1 | 2019 | 901 | 0.400 |
Why?
|
Population Surveillance | 3 | 2018 | 2614 | 0.400 |
Why?
|
Diagnosis, Differential | 10 | 2022 | 12954 | 0.400 |
Why?
|
Syndrome | 18 | 2010 | 3249 | 0.390 |
Why?
|
Gonadal Steroid Hormones | 1 | 2015 | 710 | 0.390 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2011 | 86 | 0.390 |
Why?
|
Thrombin | 2 | 2005 | 598 | 0.390 |
Why?
|
Blood Vessel Prosthesis | 3 | 2021 | 933 | 0.390 |
Why?
|
Vasopressins | 1 | 2012 | 370 | 0.390 |
Why?
|
Tomography, Optical Coherence | 6 | 2020 | 2657 | 0.390 |
Why?
|
Creatinine | 10 | 2022 | 1918 | 0.390 |
Why?
|
Breast Neoplasms | 4 | 2022 | 20827 | 0.390 |
Why?
|
Metformin | 5 | 2020 | 837 | 0.390 |
Why?
|
Family Characteristics | 2 | 2013 | 1000 | 0.380 |
Why?
|
Young Adult | 41 | 2023 | 56392 | 0.380 |
Why?
|
Tetrazoles | 5 | 2022 | 834 | 0.380 |
Why?
|
Cough | 1 | 2014 | 555 | 0.380 |
Why?
|
Polymorphism, Genetic | 6 | 2016 | 4326 | 0.380 |
Why?
|
Serine Proteinase Inhibitors | 3 | 2020 | 179 | 0.380 |
Why?
|
Counseling | 5 | 2020 | 1523 | 0.380 |
Why?
|
Physicians | 7 | 2021 | 4569 | 0.380 |
Why?
|
Arrhythmias, Cardiac | 4 | 2021 | 2267 | 0.380 |
Why?
|
Health Education | 2 | 2016 | 1056 | 0.380 |
Why?
|
Medicine | 1 | 2019 | 945 | 0.380 |
Why?
|
Dyspnea | 6 | 2023 | 1303 | 0.370 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2017 | 851 | 0.370 |
Why?
|
Spironolactone | 1 | 2014 | 382 | 0.370 |
Why?
|
Emergency Medical Services | 8 | 2020 | 1917 | 0.370 |
Why?
|
Benzazepines | 1 | 2012 | 326 | 0.370 |
Why?
|
Linear Models | 15 | 2017 | 5952 | 0.370 |
Why?
|
Aneurysm, False | 2 | 2023 | 276 | 0.360 |
Why?
|
Fellowships and Scholarships | 2 | 2017 | 1077 | 0.360 |
Why?
|
Edema | 1 | 2014 | 789 | 0.360 |
Why?
|
Withholding Treatment | 4 | 2021 | 599 | 0.360 |
Why?
|
Immunologic Factors | 1 | 2019 | 1580 | 0.360 |
Why?
|
Education, Medical, Graduate | 4 | 2017 | 2291 | 0.360 |
Why?
|
Cardiopulmonary Bypass | 2 | 2020 | 1066 | 0.360 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 436 | 0.360 |
Why?
|
Treatment Failure | 7 | 2021 | 2617 | 0.350 |
Why?
|
Clinical Competence | 8 | 2018 | 4687 | 0.350 |
Why?
|
Circadian Rhythm | 4 | 2017 | 2620 | 0.350 |
Why?
|
Aftercare | 6 | 2023 | 870 | 0.350 |
Why?
|
Office Visits | 1 | 2014 | 598 | 0.350 |
Why?
|
Cardiomyopathies | 5 | 2021 | 1911 | 0.350 |
Why?
|
Lower Extremity | 6 | 2018 | 1158 | 0.350 |
Why?
|
Muscle Strength | 1 | 2014 | 592 | 0.350 |
Why?
|
Guidelines as Topic | 6 | 2017 | 1404 | 0.350 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13691 | 0.340 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 7 | 2021 | 3047 | 0.340 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 547 | 0.340 |
Why?
|
RNA | 1 | 2019 | 2748 | 0.340 |
Why?
|
France | 7 | 2023 | 517 | 0.340 |
Why?
|
Education, Medical | 2 | 2020 | 1722 | 0.340 |
Why?
|
Insulin Resistance | 10 | 2022 | 3863 | 0.340 |
Why?
|
Antibodies, Neutralizing | 1 | 2019 | 1978 | 0.340 |
Why?
|
Anti-Ulcer Agents | 1 | 2010 | 119 | 0.340 |
Why?
|
Angiography | 6 | 2022 | 1638 | 0.340 |
Why?
|
Arterial Occlusive Diseases | 5 | 2022 | 793 | 0.340 |
Why?
|
Early Ambulation | 2 | 2006 | 44 | 0.340 |
Why?
|
Morbidity | 10 | 2024 | 1768 | 0.340 |
Why?
|
Oxygen Inhalation Therapy | 3 | 2017 | 367 | 0.330 |
Why?
|
Confidence Intervals | 9 | 2013 | 2971 | 0.330 |
Why?
|
Troponin I | 4 | 2024 | 619 | 0.330 |
Why?
|
Disease Progression | 22 | 2023 | 13273 | 0.320 |
Why?
|
Triazoles | 1 | 2014 | 904 | 0.320 |
Why?
|
Atherectomy, Coronary | 3 | 2007 | 148 | 0.320 |
Why?
|
Arachidonic Acid | 3 | 2022 | 434 | 0.320 |
Why?
|
Vegetables | 1 | 2014 | 1181 | 0.320 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2023 | 3338 | 0.320 |
Why?
|
Endoscopy | 4 | 2021 | 1781 | 0.320 |
Why?
|
Laboratories | 1 | 2012 | 462 | 0.320 |
Why?
|
Sleep Apnea, Obstructive | 7 | 2017 | 1813 | 0.320 |
Why?
|
Pyrazines | 1 | 2014 | 1230 | 0.320 |
Why?
|
Hematinics | 1 | 2011 | 280 | 0.320 |
Why?
|
Sodium Bicarbonate | 2 | 2018 | 63 | 0.320 |
Why?
|
Regional Medical Programs | 1 | 2008 | 71 | 0.320 |
Why?
|
Retreatment | 4 | 2018 | 609 | 0.320 |
Why?
|
Thoracic Surgery | 3 | 2024 | 719 | 0.310 |
Why?
|
North America | 9 | 2020 | 1249 | 0.310 |
Why?
|
Vascular Patency | 6 | 2022 | 887 | 0.310 |
Why?
|
Preventive Medicine | 2 | 2020 | 263 | 0.310 |
Why?
|
Biphenyl Compounds | 3 | 2022 | 913 | 0.310 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2134 | 0.310 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 3 | 2020 | 407 | 0.310 |
Why?
|
Hospital Charges | 2 | 2021 | 362 | 0.310 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2022 | 127 | 0.310 |
Why?
|
Health Personnel | 2 | 2020 | 3217 | 0.310 |
Why?
|
Insurance Benefits | 3 | 2020 | 183 | 0.300 |
Why?
|
Insurance Coverage | 5 | 2022 | 1900 | 0.300 |
Why?
|
Hydrocortisone | 1 | 2015 | 1826 | 0.300 |
Why?
|
Bayes Theorem | 6 | 2023 | 2307 | 0.300 |
Why?
|
Iliac Artery | 2 | 2013 | 364 | 0.300 |
Why?
|
Mass Screening | 3 | 2021 | 5251 | 0.300 |
Why?
|
Economics, Hospital | 2 | 2020 | 213 | 0.300 |
Why?
|
Minority Groups | 3 | 2021 | 1222 | 0.300 |
Why?
|
Brain Infarction | 2 | 2020 | 299 | 0.300 |
Why?
|
Dietary Supplements | 1 | 2020 | 3292 | 0.300 |
Why?
|
Fee-for-Service Plans | 4 | 2020 | 694 | 0.300 |
Why?
|
Fibroblast Growth Factors | 2 | 2023 | 878 | 0.300 |
Why?
|
Sweden | 5 | 2023 | 1341 | 0.300 |
Why?
|
Australia | 13 | 2020 | 1167 | 0.300 |
Why?
|
PPAR gamma | 2 | 2007 | 492 | 0.300 |
Why?
|
Prediabetic State | 2 | 2022 | 499 | 0.290 |
Why?
|
Catheters | 4 | 2022 | 424 | 0.290 |
Why?
|
Thienopyridines | 3 | 2010 | 12 | 0.290 |
Why?
|
Purinergic P2 Receptor Antagonists | 5 | 2012 | 71 | 0.290 |
Why?
|
Cross-Over Studies | 9 | 2022 | 2029 | 0.290 |
Why?
|
Acetylcysteine | 2 | 2018 | 271 | 0.290 |
Why?
|
Colchicine | 3 | 2023 | 244 | 0.280 |
Why?
|
Intracranial Embolism | 3 | 2021 | 202 | 0.280 |
Why?
|
Erythropoietin | 1 | 2011 | 726 | 0.280 |
Why?
|
Tricuspid Valve Insufficiency | 2 | 2023 | 349 | 0.280 |
Why?
|
Health Care Costs | 7 | 2023 | 3207 | 0.280 |
Why?
|
Aortic Rupture | 2 | 2020 | 312 | 0.280 |
Why?
|
Blood Transfusion | 6 | 2020 | 1301 | 0.280 |
Why?
|
Health Promotion | 2 | 2015 | 2205 | 0.280 |
Why?
|
Hemostasis, Surgical | 2 | 2008 | 128 | 0.270 |
Why?
|
Punctures | 4 | 2020 | 374 | 0.270 |
Why?
|
Walking | 1 | 2013 | 1182 | 0.270 |
Why?
|
Hospitalists | 1 | 2010 | 304 | 0.270 |
Why?
|
Pharmacogenetics | 4 | 2018 | 674 | 0.270 |
Why?
|
Carbonic Anhydrase II | 1 | 2005 | 23 | 0.270 |
Why?
|
Prosthesis Implantation | 3 | 2020 | 640 | 0.270 |
Why?
|
Unnecessary Procedures | 2 | 2020 | 432 | 0.270 |
Why?
|
Ontario | 7 | 2020 | 383 | 0.270 |
Why?
|
Protons | 2 | 2015 | 1129 | 0.270 |
Why?
|
Vasodilator Agents | 4 | 2020 | 974 | 0.270 |
Why?
|
Costs and Cost Analysis | 4 | 2021 | 1680 | 0.270 |
Why?
|
Glucose | 8 | 2023 | 4398 | 0.270 |
Why?
|
Sodium Chloride | 2 | 2018 | 625 | 0.270 |
Why?
|
Migraine Disorders | 1 | 2018 | 1620 | 0.270 |
Why?
|
Thromboxane B2 | 4 | 2022 | 152 | 0.260 |
Why?
|
Biological Availability | 4 | 2021 | 397 | 0.260 |
Why?
|
Heart Arrest | 4 | 2017 | 1470 | 0.260 |
Why?
|
Electrocardiography, Ambulatory | 2 | 2021 | 585 | 0.260 |
Why?
|
Helicobacter pylori | 1 | 2008 | 384 | 0.260 |
Why?
|
Hydralazine | 2 | 2016 | 38 | 0.260 |
Why?
|
Streptokinase | 1 | 2005 | 189 | 0.260 |
Why?
|
Helicobacter Infections | 1 | 2008 | 388 | 0.260 |
Why?
|
Hypertension, Pulmonary | 5 | 2020 | 1534 | 0.260 |
Why?
|
India | 6 | 2023 | 2200 | 0.260 |
Why?
|
Insurance, Health | 7 | 2021 | 2492 | 0.260 |
Why?
|
Fibrinogen | 1 | 2008 | 894 | 0.250 |
Why?
|
Isosorbide Dinitrate | 2 | 2016 | 34 | 0.250 |
Why?
|
Shock | 2 | 2018 | 318 | 0.250 |
Why?
|
Morpholines | 3 | 2013 | 571 | 0.250 |
Why?
|
Yin-Yang | 1 | 2004 | 9 | 0.250 |
Why?
|
Hyperlipoproteinemia Type II | 2 | 2020 | 375 | 0.250 |
Why?
|
Histidine | 1 | 2005 | 312 | 0.250 |
Why?
|
Hospitals, Veterans | 3 | 2017 | 404 | 0.250 |
Why?
|
Specialization | 2 | 2022 | 775 | 0.250 |
Why?
|
Adolescent | 28 | 2021 | 85729 | 0.250 |
Why?
|
Naphthyridines | 2 | 2022 | 118 | 0.250 |
Why?
|
Pyrimidines | 5 | 2024 | 2945 | 0.250 |
Why?
|
Nitric Oxide | 3 | 2021 | 2132 | 0.250 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2018 | 941 | 0.240 |
Why?
|
Burns, Electric | 1 | 2004 | 42 | 0.240 |
Why?
|
Endocarditis, Bacterial | 2 | 2019 | 455 | 0.240 |
Why?
|
New Zealand | 4 | 2018 | 355 | 0.240 |
Why?
|
Postoperative Period | 6 | 2020 | 1841 | 0.240 |
Why?
|
Reoperation | 9 | 2021 | 4200 | 0.240 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.240 |
Why?
|
Quebec | 2 | 2017 | 134 | 0.240 |
Why?
|
Marijuana Abuse | 2 | 2018 | 403 | 0.240 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4561 | 0.240 |
Why?
|
Ultrasonography | 7 | 2021 | 5986 | 0.240 |
Why?
|
Autopsy | 2 | 2018 | 1020 | 0.240 |
Why?
|
Oxidative Stress | 3 | 2019 | 3082 | 0.230 |
Why?
|
Contrast Media | 5 | 2022 | 5301 | 0.230 |
Why?
|
Intraoperative Period | 3 | 2017 | 520 | 0.230 |
Why?
|
Data Interpretation, Statistical | 5 | 2020 | 2715 | 0.230 |
Why?
|
Tachycardia, Atrioventricular Nodal Reentry | 1 | 2004 | 137 | 0.230 |
Why?
|
Air Pollution | 3 | 2023 | 2286 | 0.230 |
Why?
|
Tyrosine | 4 | 2005 | 1462 | 0.230 |
Why?
|
Hyperglycemia | 3 | 2020 | 1373 | 0.230 |
Why?
|
Lymphocyte Count | 1 | 2006 | 793 | 0.230 |
Why?
|
Early Termination of Clinical Trials | 2 | 2021 | 68 | 0.230 |
Why?
|
Medically Uninsured | 6 | 2021 | 853 | 0.230 |
Why?
|
Emergency Treatment | 2 | 2019 | 517 | 0.230 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1340 | 0.220 |
Why?
|
Emergencies | 2 | 2020 | 1170 | 0.220 |
Why?
|
Apolipoproteins B | 3 | 2022 | 374 | 0.220 |
Why?
|
Tachycardia | 2 | 2016 | 619 | 0.220 |
Why?
|
Case-Control Studies | 18 | 2022 | 21733 | 0.220 |
Why?
|
Lung Diseases | 3 | 2022 | 1887 | 0.220 |
Why?
|
Pulmonary Embolism | 2 | 2018 | 2375 | 0.220 |
Why?
|
Exercise | 4 | 2023 | 5611 | 0.210 |
Why?
|
Chronic Disease | 12 | 2021 | 9139 | 0.210 |
Why?
|
Drug Carriers | 2 | 2019 | 690 | 0.210 |
Why?
|
Catheterization | 4 | 2020 | 1469 | 0.210 |
Why?
|
Informed Consent | 2 | 2020 | 995 | 0.210 |
Why?
|
Ankle Brachial Index | 4 | 2018 | 154 | 0.210 |
Why?
|
Skilled Nursing Facilities | 6 | 2021 | 372 | 0.210 |
Why?
|
Simvastatin | 1 | 2005 | 360 | 0.210 |
Why?
|
Sympathetic Nervous System | 2 | 2015 | 513 | 0.210 |
Why?
|
Continuous Positive Airway Pressure | 3 | 2017 | 546 | 0.210 |
Why?
|
Massachusetts | 6 | 2021 | 8660 | 0.210 |
Why?
|
Pain Clinics | 1 | 2021 | 49 | 0.210 |
Why?
|
Publishing | 2 | 2020 | 833 | 0.210 |
Why?
|
International Normalized Ratio | 4 | 2023 | 367 | 0.200 |
Why?
|
Atrioventricular Block | 1 | 2023 | 120 | 0.200 |
Why?
|
Fibric Acids | 1 | 2021 | 25 | 0.200 |
Why?
|
Immunoglobulin Fragments | 1 | 2021 | 84 | 0.200 |
Why?
|
Aldosterone | 2 | 2023 | 877 | 0.200 |
Why?
|
Kidney Transplantation | 1 | 2017 | 4251 | 0.200 |
Why?
|
Genetic Loci | 4 | 2019 | 2575 | 0.200 |
Why?
|
Socioeconomic Factors | 10 | 2022 | 7784 | 0.200 |
Why?
|
Vasodilation | 2 | 2013 | 944 | 0.200 |
Why?
|
Overweight | 6 | 2022 | 2371 | 0.200 |
Why?
|
Host-Pathogen Interactions | 2 | 2020 | 1479 | 0.200 |
Why?
|
Pulmonary Artery | 4 | 2020 | 1911 | 0.200 |
Why?
|
Epoprostenol | 2 | 2012 | 254 | 0.200 |
Why?
|
Thrombotic Microangiopathies | 1 | 2023 | 132 | 0.200 |
Why?
|
Urban Population | 3 | 2020 | 2021 | 0.200 |
Why?
|
Reperfusion | 2 | 2020 | 283 | 0.200 |
Why?
|
Varicose Veins | 1 | 2003 | 154 | 0.200 |
Why?
|
Decision Support Techniques | 3 | 2020 | 1956 | 0.200 |
Why?
|
Particulate Matter | 3 | 2023 | 2529 | 0.190 |
Why?
|
Atrial Function, Left | 2 | 2020 | 173 | 0.190 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2005 | 623 | 0.190 |
Why?
|
National Library of Medicine (U.S.) | 1 | 2020 | 35 | 0.190 |
Why?
|
Ohio | 12 | 2013 | 337 | 0.190 |
Why?
|
Emergency Service, Hospital | 9 | 2021 | 7658 | 0.190 |
Why?
|
Brachiocephalic Trunk | 1 | 2020 | 44 | 0.190 |
Why?
|
Gram-Negative Anaerobic Bacteria | 1 | 2020 | 16 | 0.190 |
Why?
|
Stem Cells | 2 | 2022 | 3566 | 0.190 |
Why?
|
Niacin | 1 | 2021 | 116 | 0.190 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 103 | 0.190 |
Why?
|
Receptors, Thrombin | 2 | 2011 | 131 | 0.190 |
Why?
|
Premedication | 5 | 2005 | 258 | 0.190 |
Why?
|
Cholesterol, VLDL | 1 | 2020 | 65 | 0.190 |
Why?
|
Quality of Life | 10 | 2023 | 12788 | 0.190 |
Why?
|
Internationality | 5 | 2019 | 1002 | 0.180 |
Why?
|
Regression Analysis | 6 | 2016 | 6457 | 0.180 |
Why?
|
Pituitary-Adrenal System | 1 | 2023 | 553 | 0.180 |
Why?
|
Animals | 29 | 2022 | 168660 | 0.180 |
Why?
|
Radiography | 9 | 2014 | 7010 | 0.180 |
Why?
|
Suture Techniques | 2 | 2003 | 797 | 0.180 |
Why?
|
Peptic Ulcer | 2 | 2019 | 223 | 0.180 |
Why?
|
Insurance | 1 | 2021 | 111 | 0.180 |
Why?
|
Urban Health | 1 | 2003 | 547 | 0.180 |
Why?
|
Hemostatics | 1 | 2003 | 229 | 0.180 |
Why?
|
Models, Economic | 4 | 2018 | 712 | 0.180 |
Why?
|
Mobility Limitation | 2 | 2021 | 409 | 0.180 |
Why?
|
Galactosamine | 1 | 2019 | 30 | 0.180 |
Why?
|
Certification | 3 | 2019 | 423 | 0.180 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2023 | 844 | 0.180 |
Why?
|
Survivors | 5 | 2023 | 2291 | 0.180 |
Why?
|
Drug Costs | 3 | 2020 | 1105 | 0.180 |
Why?
|
Mustard Plant | 1 | 2019 | 15 | 0.170 |
Why?
|
Leuprolide | 1 | 2021 | 321 | 0.170 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2020 | 110 | 0.170 |
Why?
|
Quinazolinones | 2 | 2012 | 221 | 0.170 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2023 | 703 | 0.170 |
Why?
|
Pyrroles | 6 | 2023 | 1147 | 0.170 |
Why?
|
Histamine H2 Antagonists | 2 | 2010 | 165 | 0.170 |
Why?
|
Hemostatic Techniques | 2 | 2012 | 116 | 0.170 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2020 | 44 | 0.170 |
Why?
|
Sodium | 5 | 2022 | 1622 | 0.170 |
Why?
|
Friends | 1 | 2020 | 154 | 0.170 |
Why?
|
Arteriovenous Fistula | 1 | 2022 | 315 | 0.170 |
Why?
|
Patents as Topic | 1 | 2020 | 103 | 0.170 |
Why?
|
Product Labeling | 1 | 2020 | 79 | 0.170 |
Why?
|
Methylamines | 1 | 2020 | 122 | 0.170 |
Why?
|
Climatic Processes | 1 | 2018 | 3 | 0.170 |
Why?
|
Insurance Carriers | 1 | 2021 | 157 | 0.170 |
Why?
|
Reproducibility of Results | 18 | 2021 | 19894 | 0.170 |
Why?
|
Glucosyltransferases | 1 | 2019 | 98 | 0.170 |
Why?
|
Necrosis | 3 | 2008 | 1642 | 0.170 |
Why?
|
Patients | 2 | 2023 | 899 | 0.170 |
Why?
|
Breast Implantation | 1 | 2022 | 218 | 0.170 |
Why?
|
Myeloid Progenitor Cells | 1 | 2019 | 111 | 0.170 |
Why?
|
Polymers | 4 | 2020 | 1621 | 0.170 |
Why?
|
Proprotein Convertases | 2 | 2022 | 95 | 0.170 |
Why?
|
Centralized Hospital Services | 1 | 2018 | 18 | 0.170 |
Why?
|
Homocysteine | 1 | 2022 | 647 | 0.170 |
Why?
|
Fibrosis | 2 | 2023 | 2030 | 0.170 |
Why?
|
Interleukin-6 | 4 | 2022 | 3208 | 0.170 |
Why?
|
Apolipoprotein A-I | 1 | 2020 | 281 | 0.160 |
Why?
|
Embolism, Paradoxical | 1 | 2019 | 58 | 0.160 |
Why?
|
Budgets | 1 | 2020 | 229 | 0.160 |
Why?
|
Hospital Bed Capacity | 3 | 2017 | 215 | 0.160 |
Why?
|
Interleukin-10 | 1 | 2004 | 1200 | 0.160 |
Why?
|
Mitral Valve Prolapse | 1 | 2020 | 231 | 0.160 |
Why?
|
Lipoprotein Lipase | 1 | 2019 | 127 | 0.160 |
Why?
|
Amiodarone | 1 | 2020 | 211 | 0.160 |
Why?
|
Communication | 2 | 2024 | 3748 | 0.160 |
Why?
|
Computer Simulation | 6 | 2021 | 6188 | 0.160 |
Why?
|
Diet | 3 | 2022 | 7930 | 0.160 |
Why?
|
Interdisciplinary Communication | 2 | 2021 | 950 | 0.160 |
Why?
|
Menopause, Premature | 1 | 2019 | 132 | 0.160 |
Why?
|
Gastrointestinal Agents | 1 | 2023 | 494 | 0.160 |
Why?
|
Health Expenditures | 4 | 2021 | 2348 | 0.160 |
Why?
|
Thromboxanes | 2 | 2008 | 50 | 0.160 |
Why?
|
Probability | 7 | 2018 | 2505 | 0.160 |
Why?
|
Ventricular Fibrillation | 2 | 2022 | 538 | 0.160 |
Why?
|
Dissection | 1 | 2020 | 294 | 0.160 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 114 | 0.160 |
Why?
|
Granulocytes | 1 | 2020 | 548 | 0.160 |
Why?
|
Patient Care | 2 | 2022 | 638 | 0.160 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2020 | 232 | 0.160 |
Why?
|
Random Allocation | 4 | 2019 | 2429 | 0.160 |
Why?
|
Income | 2 | 2022 | 1913 | 0.160 |
Why?
|
Insulin-Secreting Cells | 3 | 2015 | 889 | 0.160 |
Why?
|
Uncertainty | 2 | 2021 | 735 | 0.160 |
Why?
|
Apolipoprotein C-III | 1 | 2019 | 202 | 0.160 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2018 | 25 | 0.160 |
Why?
|
Washington | 1 | 2018 | 314 | 0.160 |
Why?
|
Calcinosis | 2 | 2019 | 1495 | 0.160 |
Why?
|
International Classification of Diseases | 2 | 2021 | 866 | 0.160 |
Why?
|
Echocardiography, Doppler, Color | 2 | 2017 | 364 | 0.160 |
Why?
|
Government Programs | 1 | 2020 | 275 | 0.150 |
Why?
|
Sus scrofa | 5 | 2020 | 438 | 0.150 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2020 | 1354 | 0.150 |
Why?
|
Symporters | 1 | 2020 | 362 | 0.150 |
Why?
|
Calcium | 2 | 2021 | 5755 | 0.150 |
Why?
|
Patient Participation | 3 | 2021 | 1457 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 496 | 0.150 |
Why?
|
Advisory Committees | 3 | 2017 | 775 | 0.150 |
Why?
|
Glucose Tolerance Test | 2 | 2018 | 1151 | 0.150 |
Why?
|
Echocardiography, Doppler | 2 | 2019 | 935 | 0.150 |
Why?
|
Alanine Transaminase | 1 | 2020 | 593 | 0.150 |
Why?
|
Germany | 5 | 2023 | 862 | 0.150 |
Why?
|
Duodenum | 1 | 2021 | 484 | 0.150 |
Why?
|
Continuity of Patient Care | 3 | 2020 | 1049 | 0.150 |
Why?
|
Models, Biological | 4 | 2021 | 9582 | 0.150 |
Why?
|
Databases as Topic | 2 | 2018 | 474 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.150 |
Why?
|
Public Health | 2 | 2020 | 2603 | 0.150 |
Why?
|
Hyperthermia, Induced | 1 | 2021 | 404 | 0.150 |
Why?
|
Mycoses | 1 | 2020 | 376 | 0.150 |
Why?
|
Drug Utilization Review | 3 | 2016 | 245 | 0.150 |
Why?
|
Single Person | 1 | 2017 | 33 | 0.150 |
Why?
|
Hospitals, State | 1 | 2016 | 29 | 0.150 |
Why?
|
Rehabilitation Centers | 1 | 2019 | 253 | 0.150 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2023 | 555 | 0.150 |
Why?
|
Comprehensive Health Care | 1 | 2018 | 127 | 0.150 |
Why?
|
Virus Diseases | 1 | 2023 | 711 | 0.150 |
Why?
|
Heart Function Tests | 1 | 2018 | 328 | 0.150 |
Why?
|
Dosage Forms | 1 | 2017 | 56 | 0.150 |
Why?
|
Sulfonamides | 4 | 2014 | 1938 | 0.150 |
Why?
|
Vascular Resistance | 3 | 2013 | 936 | 0.150 |
Why?
|
Preoperative Care | 5 | 2021 | 2251 | 0.150 |
Why?
|
Natriuretic Peptides | 1 | 2018 | 150 | 0.150 |
Why?
|
Cardiac Valve Annuloplasty | 1 | 2017 | 50 | 0.150 |
Why?
|
Clinical Coding | 1 | 2018 | 171 | 0.150 |
Why?
|
Hospitals, University | 1 | 2019 | 570 | 0.150 |
Why?
|
Models, Statistical | 5 | 2021 | 5100 | 0.150 |
Why?
|
Benzamidines | 3 | 2001 | 25 | 0.150 |
Why?
|
Extremities | 2 | 2020 | 867 | 0.150 |
Why?
|
Hypotension | 2 | 2020 | 884 | 0.140 |
Why?
|
Heart Valves | 1 | 2018 | 291 | 0.140 |
Why?
|
Home Care Services | 3 | 2019 | 608 | 0.140 |
Why?
|
Uric Acid | 2 | 2020 | 765 | 0.140 |
Why?
|
Insulin | 8 | 2023 | 6584 | 0.140 |
Why?
|
Point-of-Care Systems | 2 | 2021 | 1177 | 0.140 |
Why?
|
Interleukin-1beta | 1 | 2022 | 973 | 0.140 |
Why?
|
Trust | 1 | 2021 | 505 | 0.140 |
Why?
|
beta Carotene | 1 | 2018 | 527 | 0.140 |
Why?
|
Long-Term Care | 2 | 2015 | 606 | 0.140 |
Why?
|
Review Literature as Topic | 1 | 2018 | 336 | 0.140 |
Why?
|
Ventricular Function, Right | 1 | 2020 | 589 | 0.140 |
Why?
|
Receptors, LDL | 1 | 2019 | 477 | 0.140 |
Why?
|
ABO Blood-Group System | 1 | 2019 | 367 | 0.140 |
Why?
|
Fluorescein Angiography | 1 | 2020 | 940 | 0.140 |
Why?
|
Hyperuricemia | 1 | 2019 | 210 | 0.140 |
Why?
|
Genotype | 10 | 2020 | 12944 | 0.140 |
Why?
|
Neovascularization, Physiologic | 3 | 2022 | 1351 | 0.140 |
Why?
|
Carotid Artery, Internal | 3 | 2021 | 445 | 0.140 |
Why?
|
Thiazolidines | 1 | 2016 | 74 | 0.140 |
Why?
|
Qualitative Research | 2 | 2022 | 2682 | 0.140 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2017 | 176 | 0.140 |
Why?
|
Critical Illness | 2 | 2020 | 2670 | 0.140 |
Why?
|
Endocarditis | 1 | 2020 | 349 | 0.140 |
Why?
|
Hobbies | 1 | 2015 | 6 | 0.140 |
Why?
|
Medicare Part C | 1 | 2020 | 296 | 0.140 |
Why?
|
Paresis | 1 | 2017 | 180 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20121 | 0.140 |
Why?
|
Oligopeptides | 1 | 2021 | 1188 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2020 | 15518 | 0.130 |
Why?
|
Bundle-Branch Block | 2 | 2022 | 269 | 0.130 |
Why?
|
Connective Tissue Diseases | 1 | 2018 | 264 | 0.130 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 2123 | 0.130 |
Why?
|
New York | 1 | 2018 | 885 | 0.130 |
Why?
|
Nitrates | 1 | 2017 | 265 | 0.130 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2019 | 962 | 0.130 |
Why?
|
Monitoring, Physiologic | 2 | 2021 | 1738 | 0.130 |
Why?
|
Equipment Design | 8 | 2018 | 3574 | 0.130 |
Why?
|
Lipoproteins, HDL | 1 | 2020 | 640 | 0.130 |
Why?
|
Caffeine | 1 | 2020 | 699 | 0.130 |
Why?
|
Thailand | 1 | 2016 | 299 | 0.130 |
Why?
|
Inflammation Mediators | 1 | 2004 | 1888 | 0.130 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2019 | 500 | 0.130 |
Why?
|
Body Weight | 3 | 2023 | 4670 | 0.130 |
Why?
|
Sample Size | 2 | 2016 | 841 | 0.130 |
Why?
|
Intermittent Claudication | 3 | 2014 | 309 | 0.130 |
Why?
|
Digoxin | 1 | 2016 | 250 | 0.130 |
Why?
|
Oximes | 3 | 2001 | 311 | 0.130 |
Why?
|
Recreation | 1 | 2015 | 115 | 0.130 |
Why?
|
HIV Infections | 2 | 2020 | 16715 | 0.130 |
Why?
|
Positron-Emission Tomography | 6 | 2023 | 6237 | 0.130 |
Why?
|
Medicare Part D | 2 | 2016 | 328 | 0.130 |
Why?
|
Standard of Care | 2 | 2021 | 564 | 0.130 |
Why?
|
Financial Management | 1 | 2016 | 160 | 0.130 |
Why?
|
Heart Failure, Systolic | 1 | 2016 | 126 | 0.120 |
Why?
|
Self Care | 1 | 2020 | 786 | 0.120 |
Why?
|
Herb-Drug Interactions | 1 | 2014 | 10 | 0.120 |
Why?
|
Pharyngitis | 1 | 2016 | 215 | 0.120 |
Why?
|
Vascular System Injuries | 1 | 2018 | 250 | 0.120 |
Why?
|
Ischemic Postconditioning | 1 | 2014 | 25 | 0.120 |
Why?
|
Genome-Wide Association Study | 7 | 2020 | 12259 | 0.120 |
Why?
|
Patient Transfer | 2 | 2018 | 762 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 35409 | 0.120 |
Why?
|
Breathing Exercises | 1 | 2014 | 53 | 0.120 |
Why?
|
Beverages | 1 | 2020 | 820 | 0.120 |
Why?
|
Gastroepiploic Artery | 1 | 2014 | 3 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.120 |
Why?
|
Pyrrolidines | 3 | 2001 | 341 | 0.120 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2727 | 0.120 |
Why?
|
Brazil | 2 | 2016 | 1264 | 0.120 |
Why?
|
Prosthesis-Related Infections | 1 | 2020 | 537 | 0.120 |
Why?
|
Disease-Free Survival | 6 | 2019 | 6895 | 0.120 |
Why?
|
Cocaine-Related Disorders | 1 | 2018 | 460 | 0.120 |
Why?
|
Lactones | 2 | 2018 | 329 | 0.120 |
Why?
|
Electric Conductivity | 5 | 2014 | 410 | 0.120 |
Why?
|
Radiation Injuries | 1 | 2022 | 1180 | 0.120 |
Why?
|
Tricuspid Valve | 1 | 2017 | 403 | 0.120 |
Why?
|
Hypertension, Renovascular | 1 | 2014 | 123 | 0.120 |
Why?
|
Longitudinal Studies | 9 | 2024 | 13980 | 0.120 |
Why?
|
Transportation of Patients | 1 | 2015 | 185 | 0.120 |
Why?
|
Alanine | 3 | 2001 | 571 | 0.120 |
Why?
|
Policy Making | 1 | 2018 | 554 | 0.120 |
Why?
|
Food, Organic | 1 | 2014 | 34 | 0.120 |
Why?
|
Remission Induction | 4 | 2020 | 2384 | 0.120 |
Why?
|
Rhabdomyolysis | 2 | 2018 | 150 | 0.120 |
Why?
|
Asia | 4 | 2017 | 609 | 0.120 |
Why?
|
Biological Transport | 1 | 2018 | 2119 | 0.120 |
Why?
|
Medical Record Linkage | 1 | 2015 | 284 | 0.120 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2018 | 499 | 0.120 |
Why?
|
Nitroglycerin | 1 | 2015 | 325 | 0.120 |
Why?
|
Dipyridamole | 2 | 2007 | 145 | 0.120 |
Why?
|
Terminology as Topic | 1 | 2021 | 1546 | 0.120 |
Why?
|
Aorta, Thoracic | 3 | 2023 | 1084 | 0.120 |
Why?
|
Balloon Occlusion | 2 | 2005 | 126 | 0.120 |
Why?
|
Brachytherapy | 2 | 2017 | 1247 | 0.120 |
Why?
|
Filtration | 2 | 2005 | 233 | 0.120 |
Why?
|
Poisson Distribution | 1 | 2015 | 513 | 0.120 |
Why?
|
Microcirculation | 1 | 2018 | 1287 | 0.120 |
Why?
|
Aircraft | 1 | 2014 | 123 | 0.120 |
Why?
|
Intestinal Diseases | 1 | 2018 | 531 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2019 | 2016 | 0.110 |
Why?
|
Motor Skills | 1 | 2017 | 522 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 629 | 0.110 |
Why?
|
Diarrhea | 1 | 2020 | 1348 | 0.110 |
Why?
|
Interleukin-17 | 1 | 2019 | 902 | 0.110 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3839 | 0.110 |
Why?
|
Ventricular Dysfunction | 1 | 2014 | 143 | 0.110 |
Why?
|
China | 5 | 2020 | 2243 | 0.110 |
Why?
|
Life Expectancy | 2 | 2018 | 1184 | 0.110 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1365 | 0.110 |
Why?
|
Respiratory Tract Diseases | 1 | 2019 | 722 | 0.110 |
Why?
|
Aneurysm, Ruptured | 1 | 2018 | 452 | 0.110 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 518 | 0.110 |
Why?
|
Neutrophils | 1 | 2006 | 3718 | 0.110 |
Why?
|
Triage | 1 | 2020 | 977 | 0.110 |
Why?
|
Boston | 4 | 2019 | 9310 | 0.110 |
Why?
|
Macular Degeneration | 1 | 2020 | 981 | 0.110 |
Why?
|
Natural Language Processing | 1 | 2021 | 1041 | 0.110 |
Why?
|
Pharmacy Service, Hospital | 1 | 2014 | 133 | 0.110 |
Why?
|
Clinical Protocols | 4 | 2017 | 1459 | 0.110 |
Why?
|
Scimitar Syndrome | 1 | 2013 | 31 | 0.110 |
Why?
|
Cell Membrane | 2 | 2021 | 3749 | 0.110 |
Why?
|
Heparin, Low-Molecular-Weight | 3 | 2008 | 339 | 0.110 |
Why?
|
Hot Temperature | 1 | 2019 | 1351 | 0.110 |
Why?
|
Suction | 1 | 2014 | 267 | 0.110 |
Why?
|
Cost Savings | 1 | 2018 | 925 | 0.110 |
Why?
|
Drug Synergism | 2 | 2009 | 1794 | 0.110 |
Why?
|
Cocaine | 1 | 2018 | 1007 | 0.110 |
Why?
|
Morphine | 1 | 2017 | 657 | 0.110 |
Why?
|
Inflammasomes | 1 | 2017 | 496 | 0.110 |
Why?
|
Professional Review Organizations | 1 | 2012 | 50 | 0.110 |
Why?
|
Corn Oil | 2 | 2023 | 29 | 0.110 |
Why?
|
Cost of Illness | 3 | 2011 | 1859 | 0.110 |
Why?
|
Liver Diseases | 2 | 2019 | 1253 | 0.110 |
Why?
|
Four-Dimensional Computed Tomography | 3 | 2020 | 145 | 0.110 |
Why?
|
CD40 Ligand | 2 | 2012 | 526 | 0.110 |
Why?
|
Models, Animal | 5 | 2020 | 2172 | 0.100 |
Why?
|
Life Support Care | 1 | 2014 | 228 | 0.100 |
Why?
|
Intraoperative Complications | 2 | 2013 | 1195 | 0.100 |
Why?
|
beta-Alanine | 1 | 2012 | 74 | 0.100 |
Why?
|
Selection Bias | 1 | 2014 | 371 | 0.100 |
Why?
|
Groin | 1 | 2012 | 105 | 0.100 |
Why?
|
Program Evaluation | 3 | 2019 | 2483 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1781 | 0.100 |
Why?
|
Respiratory Tract Infections | 2 | 2021 | 960 | 0.100 |
Why?
|
Health Care Surveys | 2 | 2017 | 2453 | 0.100 |
Why?
|
Regional Blood Flow | 2 | 2007 | 1525 | 0.100 |
Why?
|
Carotid Artery, Common | 2 | 2004 | 183 | 0.100 |
Why?
|
Lipid Metabolism | 2 | 2018 | 1885 | 0.100 |
Why?
|
Appointments and Schedules | 1 | 2016 | 417 | 0.100 |
Why?
|
Sleep Apnea Syndromes | 1 | 2020 | 944 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2017 | 1851 | 0.100 |
Why?
|
Government Regulation | 1 | 2016 | 522 | 0.100 |
Why?
|
Vitiligo | 1 | 2012 | 89 | 0.100 |
Why?
|
Air Pollutants | 2 | 2020 | 2816 | 0.100 |
Why?
|
Ghrelin | 1 | 2013 | 266 | 0.100 |
Why?
|
Pyrimidinones | 1 | 2014 | 370 | 0.100 |
Why?
|
Viral Load | 1 | 2020 | 3300 | 0.100 |
Why?
|
Editorial Policies | 1 | 2016 | 451 | 0.100 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2014 | 478 | 0.100 |
Why?
|
Sulfones | 1 | 2014 | 434 | 0.100 |
Why?
|
Weight-Bearing | 1 | 2014 | 504 | 0.100 |
Why?
|
Comparative Effectiveness Research | 2 | 2014 | 680 | 0.100 |
Why?
|
Hospice Care | 1 | 2018 | 672 | 0.100 |
Why?
|
Data Mining | 1 | 2016 | 537 | 0.100 |
Why?
|
Periplasmic Binding Proteins | 1 | 2011 | 33 | 0.100 |
Why?
|
Epoetin Alfa | 1 | 2011 | 82 | 0.100 |
Why?
|
Heptanoic Acids | 3 | 2014 | 343 | 0.100 |
Why?
|
Kidney Function Tests | 5 | 2014 | 684 | 0.100 |
Why?
|
Italy | 2 | 2023 | 829 | 0.100 |
Why?
|
Heart Ventricles | 2 | 2020 | 3817 | 0.100 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 314 | 0.100 |
Why?
|
Antibodies | 1 | 2019 | 2459 | 0.100 |
Why?
|
Pre-Eclampsia | 1 | 2020 | 1200 | 0.100 |
Why?
|
Minnesota | 2 | 2009 | 344 | 0.100 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2012 | 194 | 0.100 |
Why?
|
Tibial Arteries | 1 | 2011 | 57 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 6 | 2024 | 17439 | 0.100 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2014 | 476 | 0.090 |
Why?
|
Interleukin-18 | 1 | 2012 | 249 | 0.090 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1254 | 0.090 |
Why?
|
Intestines | 1 | 2020 | 1923 | 0.090 |
Why?
|
Total Quality Management | 1 | 2012 | 274 | 0.090 |
Why?
|
Stomach Ulcer | 1 | 2010 | 125 | 0.090 |
Why?
|
Electric Injuries | 1 | 1990 | 26 | 0.090 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2568 | 0.090 |
Why?
|
Monocytes | 1 | 2020 | 2593 | 0.090 |
Why?
|
Osteoporotic Fractures | 1 | 2015 | 401 | 0.090 |
Why?
|
Activities of Daily Living | 2 | 2017 | 2419 | 0.090 |
Why?
|
Developed Countries | 2 | 2023 | 437 | 0.090 |
Why?
|
Benchmarking | 2 | 2019 | 1042 | 0.090 |
Why?
|
Pancreatitis | 2 | 2014 | 1092 | 0.090 |
Why?
|
Drug Evaluation | 3 | 2007 | 647 | 0.090 |
Why?
|
Reference Values | 5 | 2012 | 4974 | 0.090 |
Why?
|
Communicable Diseases | 1 | 2018 | 880 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1837 | 0.090 |
Why?
|
Waist Circumference | 2 | 2011 | 917 | 0.090 |
Why?
|
Head | 1 | 2015 | 878 | 0.090 |
Why?
|
Injections, Subcutaneous | 2 | 2023 | 667 | 0.090 |
Why?
|
Drug Combinations | 4 | 2019 | 1958 | 0.090 |
Why?
|
Pneumonia, Bacterial | 1 | 2013 | 316 | 0.090 |
Why?
|
General Surgery | 1 | 2021 | 1636 | 0.090 |
Why?
|
Decision Trees | 2 | 2011 | 506 | 0.090 |
Why?
|
Intestinal Mucosa | 1 | 2021 | 3038 | 0.090 |
Why?
|
Embolism, Cholesterol | 1 | 2009 | 34 | 0.090 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2009 | 91 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1438 | 0.090 |
Why?
|
Galactose | 1 | 2011 | 306 | 0.090 |
Why?
|
Aorta | 1 | 2017 | 2062 | 0.090 |
Why?
|
Biopsy | 2 | 2023 | 6750 | 0.090 |
Why?
|
Porphyrias | 1 | 2009 | 57 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 1877 | 0.090 |
Why?
|
Risk Management | 1 | 2013 | 571 | 0.090 |
Why?
|
Analgesics | 1 | 2016 | 1040 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 441 | 0.090 |
Why?
|
Liver | 2 | 2020 | 7479 | 0.080 |
Why?
|
Brachial Artery | 1 | 2011 | 369 | 0.080 |
Why?
|
Bacteria | 1 | 2020 | 2112 | 0.080 |
Why?
|
Patient Preference | 1 | 2016 | 889 | 0.080 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2011 | 440 | 0.080 |
Why?
|
Cardiac Output | 1 | 2011 | 854 | 0.080 |
Why?
|
Melanocytes | 1 | 2012 | 515 | 0.080 |
Why?
|
Phosphatidylcholines | 1 | 2010 | 410 | 0.080 |
Why?
|
Perfusion | 2 | 2023 | 1359 | 0.080 |
Why?
|
Area Under Curve | 4 | 2018 | 1654 | 0.080 |
Why?
|
Prostheses and Implants | 3 | 2021 | 1385 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2428 | 0.080 |
Why?
|
Genetics, Population | 1 | 2014 | 933 | 0.080 |
Why?
|
Receptors, Glutamate | 1 | 2009 | 232 | 0.080 |
Why?
|
Latin America | 3 | 2017 | 379 | 0.080 |
Why?
|
Pilot Projects | 5 | 2021 | 8316 | 0.080 |
Why?
|
Adiponectin | 1 | 2014 | 1101 | 0.080 |
Why?
|
Retroperitoneal Space | 2 | 2006 | 176 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2023 | 13112 | 0.080 |
Why?
|
Brain | 3 | 2020 | 26345 | 0.080 |
Why?
|
Molecular Dynamics Simulation | 1 | 2011 | 409 | 0.080 |
Why?
|
Equipment Safety | 3 | 2008 | 263 | 0.080 |
Why?
|
Physical Examination | 1 | 2014 | 1235 | 0.080 |
Why?
|
Journal Impact Factor | 2 | 2020 | 155 | 0.080 |
Why?
|
Testosterone | 1 | 2018 | 2297 | 0.080 |
Why?
|
Creatine Kinase | 3 | 2024 | 694 | 0.080 |
Why?
|
Biomimetic Materials | 1 | 2009 | 179 | 0.080 |
Why?
|
Developing Countries | 1 | 2020 | 2815 | 0.080 |
Why?
|
Emigration and Immigration | 1 | 2010 | 402 | 0.080 |
Why?
|
Receptors, Metabotropic Glutamate | 1 | 2009 | 211 | 0.080 |
Why?
|
Pentanoic Acids | 1 | 2007 | 15 | 0.080 |
Why?
|
Administration, Inhalation | 2 | 2021 | 1105 | 0.070 |
Why?
|
Cyclic N-Oxides | 1 | 2007 | 78 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 3320 | 0.070 |
Why?
|
Age of Onset | 3 | 2021 | 3268 | 0.070 |
Why?
|
Angioscopy | 1 | 2007 | 49 | 0.070 |
Why?
|
Body Height | 2 | 2010 | 1579 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2012 | 850 | 0.070 |
Why?
|
Genetic Heterogeneity | 1 | 2010 | 733 | 0.070 |
Why?
|
Antithrombin III | 1 | 2007 | 128 | 0.070 |
Why?
|
Glucose Intolerance | 3 | 2018 | 577 | 0.070 |
Why?
|
Receptor, Cannabinoid, CB1 | 1 | 2008 | 143 | 0.070 |
Why?
|
Receptors, Purinergic P2 | 1 | 2008 | 153 | 0.070 |
Why?
|
Neuromuscular Junction | 1 | 2009 | 397 | 0.070 |
Why?
|
Deglutition Disorders | 1 | 2013 | 606 | 0.070 |
Why?
|
Computer-Aided Design | 3 | 2015 | 291 | 0.070 |
Why?
|
Perioperative Period | 2 | 2019 | 256 | 0.070 |
Why?
|
Internship and Residency | 2 | 2018 | 5787 | 0.070 |
Why?
|
Platelet Adhesiveness | 1 | 2007 | 161 | 0.070 |
Why?
|
Thermography | 1 | 2007 | 68 | 0.070 |
Why?
|
England | 2 | 2019 | 522 | 0.070 |
Why?
|
P-Selectin | 2 | 2006 | 601 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2018 | 2899 | 0.070 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2023 | 340 | 0.070 |
Why?
|
Forced Expiratory Volume | 2 | 2021 | 1740 | 0.070 |
Why?
|
Early Diagnosis | 3 | 2018 | 1186 | 0.070 |
Why?
|
Rats | 4 | 2022 | 24250 | 0.070 |
Why?
|
Rupture, Spontaneous | 1 | 2007 | 354 | 0.070 |
Why?
|
Focus Groups | 2 | 2021 | 1320 | 0.070 |
Why?
|
Cell Proliferation | 2 | 2012 | 10477 | 0.070 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 1184 | 0.070 |
Why?
|
Substance-Related Disorders | 2 | 2021 | 4254 | 0.070 |
Why?
|
Calcium-Binding Proteins | 1 | 2011 | 1081 | 0.070 |
Why?
|
Diabetic Retinopathy | 1 | 2015 | 1211 | 0.070 |
Why?
|
Lung | 2 | 2021 | 9858 | 0.070 |
Why?
|
Electrophysiology | 2 | 2009 | 1297 | 0.070 |
Why?
|
Cell Adhesion | 1 | 2012 | 3144 | 0.070 |
Why?
|
Phantoms, Imaging | 2 | 2014 | 2479 | 0.070 |
Why?
|
Preoperative Period | 2 | 2018 | 550 | 0.070 |
Why?
|
Critical Pathways | 2 | 2023 | 476 | 0.070 |
Why?
|
Hematocrit | 2 | 2022 | 636 | 0.060 |
Why?
|
Hydrogen Bonding | 1 | 2005 | 291 | 0.060 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 3677 | 0.060 |
Why?
|
Wound Healing | 1 | 2016 | 2776 | 0.060 |
Why?
|
Heterozygote | 1 | 2012 | 2803 | 0.060 |
Why?
|
Antiphospholipid Syndrome | 1 | 2007 | 173 | 0.060 |
Why?
|
Muscles | 1 | 1990 | 1613 | 0.060 |
Why?
|
Calibration | 2 | 2018 | 816 | 0.060 |
Why?
|
Crystallography, X-Ray | 2 | 2011 | 2011 | 0.060 |
Why?
|
Bibliometrics | 2 | 2019 | 338 | 0.060 |
Why?
|
Endothelial Cells | 2 | 2021 | 3482 | 0.060 |
Why?
|
Threonine | 1 | 2005 | 279 | 0.060 |
Why?
|
Vascular Grafting | 2 | 2017 | 143 | 0.060 |
Why?
|
Graft Rejection | 1 | 2018 | 4398 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4477 | 0.060 |
Why?
|
Pipecolic Acids | 1 | 2005 | 76 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 3794 | 0.060 |
Why?
|
Artifacts | 1 | 2013 | 1904 | 0.060 |
Why?
|
Epidemiologic Methods | 4 | 2011 | 1364 | 0.060 |
Why?
|
Optics and Photonics | 1 | 2006 | 319 | 0.060 |
Why?
|
Chromosome Mapping | 1 | 2013 | 4737 | 0.060 |
Why?
|
Mendelian Randomization Analysis | 2 | 2020 | 967 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 13028 | 0.060 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2009 | 717 | 0.060 |
Why?
|
Internet | 2 | 2014 | 3058 | 0.060 |
Why?
|
History, 21st Century | 2 | 2021 | 1532 | 0.060 |
Why?
|
Patient Compliance | 4 | 2017 | 2683 | 0.060 |
Why?
|
Valine | 1 | 2006 | 413 | 0.060 |
Why?
|
Hemostasis | 1 | 2006 | 458 | 0.060 |
Why?
|
Magnetic Resonance Angiography | 2 | 2018 | 1444 | 0.060 |
Why?
|
Benzylamines | 1 | 2005 | 223 | 0.060 |
Why?
|
Catalysis | 1 | 2005 | 762 | 0.060 |
Why?
|
Thromboxane A2 | 1 | 2003 | 93 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2018 | 4041 | 0.060 |
Why?
|
Cannabinoids | 1 | 2006 | 166 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2021 | 14714 | 0.060 |
Why?
|
Azetidines | 1 | 2005 | 142 | 0.060 |
Why?
|
Japan | 3 | 2017 | 1360 | 0.060 |
Why?
|
Cross Infection | 1 | 2013 | 1416 | 0.060 |
Why?
|
Medication Therapy Management | 2 | 2016 | 127 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2014 | 1222 | 0.060 |
Why?
|
Genetic Variation | 1 | 2019 | 6535 | 0.060 |
Why?
|
Hematologic Agents | 1 | 2003 | 39 | 0.060 |
Why?
|
Fractures, Bone | 1 | 2015 | 1946 | 0.060 |
Why?
|
Telemedicine | 1 | 2020 | 2874 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5691 | 0.060 |
Why?
|
Bhutan | 1 | 2023 | 60 | 0.060 |
Why?
|
Factor XIa | 1 | 2022 | 8 | 0.060 |
Why?
|
Sick Sinus Syndrome | 1 | 2023 | 44 | 0.060 |
Why?
|
Hyperinsulinism | 1 | 2006 | 414 | 0.060 |
Why?
|
Flow Cytometry | 3 | 2009 | 5973 | 0.060 |
Why?
|
Therapeutic Equivalency | 2 | 2019 | 141 | 0.060 |
Why?
|
Feasibility Studies | 3 | 2021 | 5078 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9440 | 0.050 |
Why?
|
Metabolic Diseases | 1 | 2009 | 658 | 0.050 |
Why?
|
Salicylic Acid | 1 | 2022 | 56 | 0.050 |
Why?
|
Protein Conformation | 1 | 2011 | 4009 | 0.050 |
Why?
|
Mineralocorticoids | 1 | 2022 | 38 | 0.050 |
Why?
|
Subtilisins | 1 | 2022 | 83 | 0.050 |
Why?
|
Educational Status | 1 | 2010 | 2540 | 0.050 |
Why?
|
Superior Vena Cava Syndrome | 1 | 2002 | 53 | 0.050 |
Why?
|
Bone Density | 1 | 2015 | 3460 | 0.050 |
Why?
|
Tablets | 1 | 2022 | 145 | 0.050 |
Why?
|
Ramipril | 1 | 2022 | 95 | 0.050 |
Why?
|
Software | 1 | 2016 | 4440 | 0.050 |
Why?
|
Capsules | 1 | 2022 | 196 | 0.050 |
Why?
|
Fluoroscopy | 2 | 2021 | 924 | 0.050 |
Why?
|
Polysaccharides | 1 | 2009 | 1058 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2014 | 3391 | 0.050 |
Why?
|
Carotid Artery, External | 1 | 2001 | 38 | 0.050 |
Why?
|
Peroxynitrous Acid | 1 | 2021 | 41 | 0.050 |
Why?
|
DNA | 1 | 2016 | 7295 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2007 | 970 | 0.050 |
Why?
|
Drosophila | 1 | 2009 | 1494 | 0.050 |
Why?
|
Sclerotherapy | 1 | 2003 | 175 | 0.050 |
Why?
|
Beds | 1 | 2021 | 48 | 0.050 |
Why?
|
Ultrasonography, Doppler, Duplex | 2 | 2018 | 205 | 0.050 |
Why?
|
Research Support as Topic | 2 | 2017 | 705 | 0.050 |
Why?
|
Platelet Count | 2 | 2018 | 780 | 0.050 |
Why?
|
New York City | 2 | 2019 | 705 | 0.050 |
Why?
|
Scattering, Small Angle | 1 | 2021 | 59 | 0.050 |
Why?
|
Sampling Studies | 1 | 2003 | 622 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4422 | 0.050 |
Why?
|
Dependent Ambulation | 1 | 2021 | 13 | 0.050 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2022 | 164 | 0.050 |
Why?
|
Whole Blood Coagulation Time | 1 | 2001 | 30 | 0.050 |
Why?
|
Zinc | 1 | 2005 | 683 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2007 | 3480 | 0.050 |
Why?
|
Psychomotor Agitation | 1 | 2023 | 293 | 0.050 |
Why?
|
Bandages | 1 | 2003 | 266 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2013 | 3187 | 0.050 |
Why?
|
Arginine | 1 | 2005 | 943 | 0.050 |
Why?
|
Linoleic Acid | 1 | 2022 | 157 | 0.050 |
Why?
|
Basilar Artery | 1 | 2022 | 200 | 0.050 |
Why?
|
Axillary Artery | 1 | 2020 | 50 | 0.050 |
Why?
|
HIV Envelope Protein gp120 | 1 | 2005 | 952 | 0.050 |
Why?
|
X-Ray Diffraction | 1 | 2021 | 420 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2005 | 1793 | 0.050 |
Why?
|
Aging | 1 | 2019 | 8655 | 0.050 |
Why?
|
Receptors, CXCR4 | 1 | 2005 | 727 | 0.050 |
Why?
|
Esters | 1 | 2021 | 210 | 0.050 |
Why?
|
Administration, Cutaneous | 1 | 2003 | 710 | 0.050 |
Why?
|
Up-Regulation | 2 | 2020 | 4221 | 0.050 |
Why?
|
Placebo Effect | 2 | 2018 | 503 | 0.050 |
Why?
|
Monocrotaline | 1 | 2020 | 26 | 0.050 |
Why?
|
Food-Drug Interactions | 1 | 2020 | 27 | 0.050 |
Why?
|
Vaccines, Inactivated | 1 | 2021 | 184 | 0.050 |
Why?
|
Hemorrhagic Disorders | 1 | 2020 | 36 | 0.050 |
Why?
|
Neprilysin | 1 | 2023 | 439 | 0.050 |
Why?
|
Pericardiocentesis | 1 | 2020 | 74 | 0.050 |
Why?
|
Cell Movement | 1 | 2012 | 5216 | 0.050 |
Why?
|
Sulfhydryl Compounds | 1 | 2021 | 298 | 0.050 |
Why?
|
Equipment and Supplies | 1 | 2003 | 281 | 0.050 |
Why?
|
Vertebrobasilar Insufficiency | 1 | 2001 | 114 | 0.050 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2021 | 227 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2007 | 1431 | 0.040 |
Why?
|
Swine | 3 | 2017 | 5909 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2020 | 6356 | 0.040 |
Why?
|
Quality Control | 2 | 2014 | 841 | 0.040 |
Why?
|
Intraoperative Care | 1 | 2003 | 767 | 0.040 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 1108 | 0.040 |
Why?
|
Models, Molecular | 2 | 2011 | 5445 | 0.040 |
Why?
|
Cobalt | 1 | 2020 | 158 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2012 | 19232 | 0.040 |
Why?
|
Publication Bias | 1 | 2020 | 162 | 0.040 |
Why?
|
Tetraploidy | 1 | 2019 | 29 | 0.040 |
Why?
|
Vasculitis | 1 | 2004 | 519 | 0.040 |
Why?
|
Ultrasonics | 1 | 2020 | 212 | 0.040 |
Why?
|
Prescriptions | 1 | 2022 | 387 | 0.040 |
Why?
|
Child | 3 | 2020 | 77637 | 0.040 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2020 | 116 | 0.040 |
Why?
|
Chromium | 1 | 2020 | 123 | 0.040 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2022 | 251 | 0.040 |
Why?
|
Fish Oils | 1 | 2023 | 470 | 0.040 |
Why?
|
X-Ray Microtomography | 1 | 2021 | 428 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2020 | 403 | 0.040 |
Why?
|
Interleukins | 1 | 2004 | 791 | 0.040 |
Why?
|
Mexico | 2 | 2012 | 689 | 0.040 |
Why?
|
Pericardium | 1 | 2023 | 667 | 0.040 |
Why?
|
Hyperparathyroidism | 1 | 2020 | 339 | 0.040 |
Why?
|
Vital Capacity | 1 | 2021 | 925 | 0.040 |
Why?
|
Rain | 1 | 2018 | 61 | 0.040 |
Why?
|
Malaysia | 1 | 2018 | 92 | 0.040 |
Why?
|
Freedom | 1 | 2018 | 69 | 0.040 |
Why?
|
Michigan | 1 | 2019 | 350 | 0.040 |
Why?
|
Information Systems | 1 | 2021 | 410 | 0.040 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2022 | 546 | 0.040 |
Why?
|
Amides | 1 | 2021 | 459 | 0.040 |
Why?
|
Neurologic Examination | 2 | 2016 | 929 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11059 | 0.040 |
Why?
|
North Carolina | 1 | 2019 | 315 | 0.040 |
Why?
|
Gene Expression Regulation, Plant | 1 | 2019 | 198 | 0.040 |
Why?
|
Matched-Pair Analysis | 1 | 2019 | 288 | 0.040 |
Why?
|
Alloys | 3 | 2004 | 122 | 0.040 |
Why?
|
Policy | 1 | 2022 | 508 | 0.040 |
Why?
|
Emergency Medicine | 1 | 2008 | 1205 | 0.040 |
Why?
|
Insurance Claim Review | 2 | 2015 | 719 | 0.040 |
Why?
|
Societies, Scientific | 1 | 2019 | 220 | 0.040 |
Why?
|
Decision Support Systems, Clinical | 2 | 2020 | 1164 | 0.040 |
Why?
|
Risk Adjustment | 1 | 2022 | 594 | 0.040 |
Why?
|
Bronchodilator Agents | 1 | 2021 | 502 | 0.040 |
Why?
|
Spain | 1 | 2019 | 464 | 0.040 |
Why?
|
Diuresis | 1 | 2018 | 116 | 0.040 |
Why?
|
Rats, Zucker | 1 | 2017 | 128 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2022 | 1892 | 0.040 |
Why?
|
Markov Chains | 2 | 2011 | 968 | 0.040 |
Why?
|
ROC Curve | 2 | 2010 | 3527 | 0.040 |
Why?
|
No-Reflow Phenomenon | 1 | 2017 | 14 | 0.040 |
Why?
|
Antidotes | 1 | 2018 | 138 | 0.040 |
Why?
|
Environmental Exposure | 2 | 2024 | 4232 | 0.040 |
Why?
|
Evidence-Based Practice | 2 | 2012 | 500 | 0.040 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2017 | 25 | 0.040 |
Why?
|
Norepinephrine | 2 | 2014 | 909 | 0.040 |
Why?
|
Apoptosis | 2 | 2012 | 9718 | 0.040 |
Why?
|
Veterans Health | 1 | 2019 | 216 | 0.040 |
Why?
|
Education | 1 | 2020 | 543 | 0.040 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2019 | 235 | 0.040 |
Why?
|
Hospices | 1 | 2021 | 265 | 0.040 |
Why?
|
Signal Transduction | 3 | 2019 | 23398 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2023 | 1683 | 0.040 |
Why?
|
Ovariectomy | 1 | 2019 | 661 | 0.040 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2019 | 264 | 0.040 |
Why?
|
Leukocytes | 1 | 2005 | 2044 | 0.040 |
Why?
|
Body Composition | 2 | 2018 | 2401 | 0.040 |
Why?
|
Goals | 1 | 2022 | 708 | 0.040 |
Why?
|
Cicatrix | 1 | 2023 | 763 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2020 | 559 | 0.040 |
Why?
|
Stress, Mechanical | 2 | 2013 | 1684 | 0.040 |
Why?
|
Procollagen | 1 | 2017 | 185 | 0.040 |
Why?
|
Plant Proteins | 1 | 2019 | 364 | 0.040 |
Why?
|
Physician Incentive Plans | 1 | 2018 | 161 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2014 | 5264 | 0.030 |
Why?
|
Neointima | 1 | 2017 | 135 | 0.030 |
Why?
|
Republic of Korea | 1 | 2018 | 538 | 0.030 |
Why?
|
South America | 1 | 2016 | 181 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 892 | 0.030 |
Why?
|
Integrins | 1 | 2001 | 846 | 0.030 |
Why?
|
Eating | 1 | 2023 | 1536 | 0.030 |
Why?
|
Ambulances | 1 | 2016 | 95 | 0.030 |
Why?
|
Ultrasonography, Doppler | 2 | 2011 | 458 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2019 | 669 | 0.030 |
Why?
|
Limb Salvage | 1 | 2018 | 433 | 0.030 |
Why?
|
Florida | 1 | 2017 | 435 | 0.030 |
Why?
|
Stem Cell Niche | 1 | 2019 | 346 | 0.030 |
Why?
|
Multigene Family | 1 | 2019 | 1101 | 0.030 |
Why?
|
Glyburide | 1 | 2016 | 113 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2017 | 813 | 0.030 |
Why?
|
Thoracic Injuries | 1 | 2018 | 272 | 0.030 |
Why?
|
Cineangiography | 1 | 2014 | 124 | 0.030 |
Why?
|
Polysomnography | 1 | 2021 | 1776 | 0.030 |
Why?
|
Partial Thromboplastin Time | 2 | 2007 | 206 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2017 | 438 | 0.030 |
Why?
|
Sulfonylurea Compounds | 1 | 2016 | 205 | 0.030 |
Why?
|
Alzheimer Disease | 1 | 2016 | 8035 | 0.030 |
Why?
|
Patient Care Management | 1 | 2018 | 306 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2021 | 2712 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 805 | 0.030 |
Why?
|
Documentation | 1 | 2020 | 871 | 0.030 |
Why?
|
Gene Frequency | 2 | 2012 | 3585 | 0.030 |
Why?
|
Access to Information | 1 | 2017 | 320 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2019 | 708 | 0.030 |
Why?
|
Safety | 1 | 2019 | 1184 | 0.030 |
Why?
|
Death | 1 | 2019 | 678 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 2015 | 240 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2019 | 783 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3550 | 0.030 |
Why?
|
Electroencephalography | 1 | 2009 | 6061 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2019 | 1213 | 0.030 |
Why?
|
Environmental Monitoring | 1 | 2020 | 1413 | 0.030 |
Why?
|
Pregnancy | 3 | 2020 | 29140 | 0.030 |
Why?
|
Intestinal Perforation | 1 | 2016 | 253 | 0.030 |
Why?
|
Pressoreceptors | 1 | 2014 | 100 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2019 | 695 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 847 | 0.030 |
Why?
|
Down-Regulation | 1 | 2021 | 3000 | 0.030 |
Why?
|
Platelet Membrane Glycoprotein IIb | 1 | 2013 | 53 | 0.030 |
Why?
|
Acylation | 1 | 2013 | 107 | 0.030 |
Why?
|
Brain Mapping | 1 | 2009 | 6622 | 0.030 |
Why?
|
Fundus Oculi | 1 | 2015 | 473 | 0.030 |
Why?
|
Electric Impedance | 1 | 2018 | 729 | 0.030 |
Why?
|
Health Care Sector | 1 | 2015 | 194 | 0.030 |
Why?
|
Drug Industry | 1 | 2020 | 746 | 0.030 |
Why?
|
International Agencies | 1 | 2014 | 240 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 788 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2017 | 593 | 0.030 |
Why?
|
Serum Albumin | 1 | 2016 | 675 | 0.030 |
Why?
|
Cognition | 2 | 2023 | 6759 | 0.030 |
Why?
|
Observer Variation | 1 | 1999 | 2592 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2019 | 814 | 0.030 |
Why?
|
Venous Insufficiency | 1 | 2014 | 103 | 0.030 |
Why?
|
Infusions, Parenteral | 1 | 2013 | 419 | 0.030 |
Why?
|
Directive Counseling | 1 | 2014 | 166 | 0.030 |
Why?
|
Therapy, Computer-Assisted | 1 | 2015 | 271 | 0.030 |
Why?
|
Blood Vessels | 1 | 2019 | 1124 | 0.030 |
Why?
|
Diet, Atherogenic | 1 | 2013 | 96 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2022 | 11478 | 0.030 |
Why?
|
Medical Assistance | 1 | 2013 | 104 | 0.030 |
Why?
|
Integrin beta3 | 1 | 2013 | 122 | 0.030 |
Why?
|
Aryldialkylphosphatase | 1 | 2013 | 63 | 0.030 |
Why?
|
Netherlands | 1 | 2017 | 2170 | 0.030 |
Why?
|
Erythrocytes | 1 | 2022 | 2455 | 0.030 |
Why?
|
Polypharmacy | 1 | 2015 | 294 | 0.030 |
Why?
|
Drug Antagonism | 1 | 2012 | 50 | 0.030 |
Why?
|
Device Approval | 1 | 2014 | 163 | 0.030 |
Why?
|
Shear Strength | 1 | 2013 | 165 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 2018 | 1011 | 0.030 |
Why?
|
Medical Staff Privileges | 1 | 2012 | 14 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1854 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2018 | 915 | 0.030 |
Why?
|
Foundations | 1 | 2012 | 94 | 0.030 |
Why?
|
Fluorobenzenes | 1 | 2014 | 183 | 0.030 |
Why?
|
Arteries | 2 | 2008 | 1119 | 0.030 |
Why?
|
Glycemic Index | 1 | 2015 | 394 | 0.030 |
Why?
|
Antigens, CD | 2 | 2018 | 4026 | 0.030 |
Why?
|
Frail Elderly | 1 | 2017 | 693 | 0.030 |
Why?
|
Electrodes | 1 | 2014 | 616 | 0.030 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2013 | 264 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2016 | 424 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2013 | 379 | 0.030 |
Why?
|
Temperature | 1 | 2018 | 2202 | 0.030 |
Why?
|
Discriminant Analysis | 1 | 2012 | 229 | 0.030 |
Why?
|
Postprandial Period | 1 | 2013 | 293 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2018 | 1869 | 0.030 |
Why?
|
Knowledge Bases | 1 | 2012 | 85 | 0.030 |
Why?
|
Hypogonadism | 1 | 2018 | 752 | 0.030 |
Why?
|
General Practitioners | 1 | 2013 | 103 | 0.030 |
Why?
|
Menopause | 1 | 2019 | 1626 | 0.030 |
Why?
|
Apolipoprotein E4 | 1 | 2016 | 668 | 0.030 |
Why?
|
Phylogeny | 1 | 2019 | 2796 | 0.030 |
Why?
|
Tubulin Modulators | 1 | 2012 | 110 | 0.030 |
Why?
|
Needs Assessment | 1 | 2018 | 1146 | 0.030 |
Why?
|
Oxygen | 2 | 2014 | 4189 | 0.020 |
Why?
|
History, 20th Century | 1 | 2019 | 2736 | 0.020 |
Why?
|
Denmark | 1 | 2014 | 738 | 0.020 |
Why?
|
Differential Thermal Analysis | 1 | 2011 | 1 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2017 | 1152 | 0.020 |
Why?
|
Models, Anatomic | 1 | 2015 | 690 | 0.020 |
Why?
|
Apoenzymes | 1 | 2011 | 16 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2018 | 1347 | 0.020 |
Why?
|
Oximetry | 1 | 2014 | 471 | 0.020 |
Why?
|
Holoenzymes | 1 | 2011 | 41 | 0.020 |
Why?
|
Indiana | 1 | 2011 | 92 | 0.020 |
Why?
|
Information Storage and Retrieval | 1 | 2016 | 824 | 0.020 |
Why?
|
Interleukin-11 | 1 | 2010 | 63 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2018 | 1828 | 0.020 |
Why?
|
Membranes, Artificial | 1 | 2012 | 371 | 0.020 |
Why?
|
Macrophages | 1 | 2005 | 5651 | 0.020 |
Why?
|
Carotid Artery Thrombosis | 1 | 2010 | 53 | 0.020 |
Why?
|
Polyesters | 1 | 2012 | 362 | 0.020 |
Why?
|
General Practice | 1 | 2012 | 100 | 0.020 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2011 | 169 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1108 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2017 | 1602 | 0.020 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 808 | 0.020 |
Why?
|
Conflict of Interest | 1 | 2015 | 544 | 0.020 |
Why?
|
Rabbits | 1 | 2017 | 4894 | 0.020 |
Why?
|
Peer Review | 1 | 2012 | 209 | 0.020 |
Why?
|
Regeneration | 1 | 2019 | 1486 | 0.020 |
Why?
|
Cerebrovascular Circulation | 1 | 2020 | 2732 | 0.020 |
Why?
|
Smad3 Protein | 1 | 2010 | 180 | 0.020 |
Why?
|
Skin Pigmentation | 1 | 2012 | 282 | 0.020 |
Why?
|
Nomograms | 1 | 2012 | 228 | 0.020 |
Why?
|
Time | 1 | 2012 | 542 | 0.020 |
Why?
|
Loneliness | 1 | 2012 | 186 | 0.020 |
Why?
|
Cycloleucine | 1 | 2009 | 9 | 0.020 |
Why?
|
Statistics as Topic | 2 | 2009 | 2369 | 0.020 |
Why?
|
Phenotype | 2 | 2020 | 16361 | 0.020 |
Why?
|
Pressure | 1 | 2013 | 1205 | 0.020 |
Why?
|
Singapore | 1 | 2010 | 295 | 0.020 |
Why?
|
Tissue Scaffolds | 1 | 2017 | 956 | 0.020 |
Why?
|
Private Sector | 1 | 2013 | 393 | 0.020 |
Why?
|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2009 | 70 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3639 | 0.020 |
Why?
|
Saskatchewan | 1 | 2009 | 9 | 0.020 |
Why?
|
Leptin | 1 | 2018 | 1600 | 0.020 |
Why?
|
Receptors, Kainic Acid | 1 | 2009 | 88 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2018 | 4777 | 0.020 |
Why?
|
Taiwan | 1 | 2010 | 497 | 0.020 |
Why?
|
Isoenzymes | 2 | 2005 | 1728 | 0.020 |
Why?
|
Kainic Acid | 1 | 2009 | 199 | 0.020 |
Why?
|
Suburban Population | 1 | 2009 | 55 | 0.020 |
Why?
|
Anemia, Macrocytic | 1 | 2009 | 55 | 0.020 |
Why?
|
Thiazoles | 1 | 2016 | 1482 | 0.020 |
Why?
|
Cultural Characteristics | 1 | 2010 | 261 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2018 | 1539 | 0.020 |
Why?
|
Israel | 1 | 2011 | 796 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1990 | 2184 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2014 | 1073 | 0.020 |
Why?
|
Disulfides | 1 | 2011 | 457 | 0.020 |
Why?
|
Antidepressive Agents | 1 | 2021 | 2837 | 0.020 |
Why?
|
Bone Marrow | 1 | 2019 | 2951 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2020 | 8300 | 0.020 |
Why?
|
Prescription Drugs | 1 | 2015 | 593 | 0.020 |
Why?
|
Consumer Product Safety | 1 | 2009 | 122 | 0.020 |
Why?
|
Erythrocyte Indices | 1 | 2009 | 146 | 0.020 |
Why?
|
Afferent Pathways | 1 | 2009 | 302 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1990 | 960 | 0.020 |
Why?
|
Hyperplasia | 1 | 2011 | 1185 | 0.020 |
Why?
|
Infrared Rays | 1 | 2009 | 249 | 0.020 |
Why?
|
Glutamates | 1 | 2009 | 397 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2017 | 2440 | 0.020 |
Why?
|
Excitatory Postsynaptic Potentials | 1 | 2009 | 377 | 0.020 |
Why?
|
HIV-1 | 1 | 2005 | 6939 | 0.020 |
Why?
|
Ankle | 1 | 2011 | 327 | 0.020 |
Why?
|
Larva | 1 | 2009 | 515 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2019 | 3622 | 0.020 |
Why?
|
Receptors, AMPA | 1 | 2009 | 332 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2013 | 1725 | 0.020 |
Why?
|
Cell Size | 1 | 2009 | 641 | 0.020 |
Why?
|
Lactic Acid | 1 | 2012 | 1131 | 0.020 |
Why?
|
Learning | 1 | 2017 | 1710 | 0.020 |
Why?
|
Lupus Coagulation Inhibitor | 1 | 2007 | 31 | 0.020 |
Why?
|
Observation | 1 | 2009 | 312 | 0.020 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2007 | 115 | 0.020 |
Why?
|
Cerebral Arteries | 1 | 2009 | 494 | 0.020 |
Why?
|
Hemoglobins | 2 | 2004 | 1531 | 0.020 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2008 | 138 | 0.020 |
Why?
|
Prothrombin | 1 | 2007 | 185 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2014 | 1372 | 0.020 |
Why?
|
Physician's Role | 1 | 2014 | 942 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2009 | 864 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2760 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 2015 | 884 | 0.020 |
Why?
|
Pneumonia | 1 | 2018 | 2133 | 0.020 |
Why?
|
Curriculum | 1 | 2019 | 3603 | 0.020 |
Why?
|
Visual Acuity | 1 | 2015 | 2525 | 0.020 |
Why?
|
Long QT Syndrome | 1 | 2010 | 453 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2014 | 2018 | 0.020 |
Why?
|
Hip Fractures | 1 | 2014 | 955 | 0.020 |
Why?
|
Health Services Research | 1 | 2013 | 1836 | 0.020 |
Why?
|
Mutation | 2 | 2010 | 29777 | 0.020 |
Why?
|
Pravastatin | 1 | 2007 | 395 | 0.020 |
Why?
|
Monitoring, Ambulatory | 1 | 2008 | 358 | 0.020 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2007 | 419 | 0.020 |
Why?
|
Intramolecular Transferases | 1 | 2004 | 15 | 0.020 |
Why?
|
Anthropometry | 1 | 2009 | 1348 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 6934 | 0.020 |
Why?
|
Diet, Reducing | 1 | 2008 | 462 | 0.020 |
Why?
|
Amino Acids | 1 | 2011 | 1733 | 0.020 |
Why?
|
Medical History Taking | 1 | 2008 | 782 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7793 | 0.010 |
Why?
|
Ireland | 1 | 2004 | 161 | 0.010 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2005 | 293 | 0.010 |
Why?
|
Middle Cerebral Artery | 1 | 2005 | 264 | 0.010 |
Why?
|
Atropine | 1 | 2004 | 244 | 0.010 |
Why?
|
International Cooperation | 1 | 2010 | 1419 | 0.010 |
Why?
|
Louisiana | 1 | 2003 | 108 | 0.010 |
Why?
|
Benzodiazepines | 1 | 2009 | 1101 | 0.010 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2004 | 177 | 0.010 |
Why?
|
Economics, Pharmaceutical | 1 | 2003 | 87 | 0.010 |
Why?
|
Synaptic Transmission | 1 | 2009 | 1176 | 0.010 |
Why?
|
Factor Xa | 1 | 2004 | 162 | 0.010 |
Why?
|
Depression | 2 | 2016 | 7760 | 0.010 |
Why?
|
Causality | 1 | 2009 | 1275 | 0.010 |
Why?
|
Protein Precursors | 1 | 2007 | 1154 | 0.010 |
Why?
|
Pennsylvania | 1 | 2003 | 613 | 0.010 |
Why?
|
Employment | 1 | 2009 | 1132 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7172 | 0.010 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2001 | 50 | 0.010 |
Why?
|
Computational Biology | 1 | 2014 | 3515 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2005 | 880 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4288 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 2480 | 0.010 |
Why?
|
Bleeding Time | 1 | 2000 | 89 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2005 | 2256 | 0.010 |
Why?
|
Pain | 1 | 2016 | 4987 | 0.010 |
Why?
|
Infant | 1 | 2022 | 35122 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2016 | 4245 | 0.010 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2001 | 337 | 0.010 |
Why?
|
Asthma | 1 | 2019 | 6010 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2008 | 1070 | 0.010 |
Why?
|
Suicide | 1 | 2010 | 1476 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 40964 | 0.010 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2003 | 430 | 0.010 |
Why?
|
Hematoma | 1 | 2003 | 758 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2005 | 1836 | 0.010 |
Why?
|
Escherichia coli | 1 | 2011 | 4216 | 0.010 |
Why?
|
Protein Binding | 1 | 2011 | 9377 | 0.010 |
Why?
|
Health Surveys | 1 | 2008 | 4036 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1999 | 771 | 0.010 |
Why?
|
Virus Replication | 1 | 2005 | 2535 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 1999 | 693 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 3874 | 0.010 |
Why?
|
Lymphokines | 1 | 1999 | 948 | 0.010 |
Why?
|
Headache | 1 | 2004 | 1224 | 0.010 |
Why?
|
Demography | 1 | 2001 | 1653 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 2883 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18027 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 13809 | 0.010 |
Why?
|
Primary Health Care | 1 | 2010 | 4556 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 18107 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2001 | 2037 | 0.010 |
Why?
|
Mental Disorders | 1 | 2010 | 6593 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 1999 | 3510 | 0.000 |
Why?
|